View Filing Data

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2012	Mar. 01, 2013	Jun. 30, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	TG THERAPEUTICS, INC.
Entity Central Index Key	0001001316
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	tgtx
Entity Common Stock, Shares Outstanding		25,820,738
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2012
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2012
Entity Well-Known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 69,293,694

Consolidated Balance Sheets - USD ($)	Dec. 31, 2012	Dec. 31, 2011
Assets
Cash and cash equivalents	$ 16,455,995	$ 9,748,491
Prepaid research and development	1,990,759
Other current assets	29,128	87,176
Total current assets	18,475,882	9,835,667
Equipment, net	1,164	0
In-process research and development	2,797,600	3,902,300
Goodwill	799,391	799,391
Total assets	22,074,037	14,537,358
Liabilities and equity
Notes payable, current portion	677,778	877,778
Accounts payable and accrued expenses	1,117,397	666,640
Accrued compensation	145,000	0
Current portion of deferred revenue	152,381	0
Interest payable, current portion	123,511	61,941
Total current liabilities	2,216,067	1,606,359
Deferred revenue, net of current portion	1,828,571	0
Notes payable, less current portion, at fair value	2,479,098	3,294,797
Total liabilities	6,523,736	4,901,156
Commitments and contingencies
Equity:
Preferred stock, $0.001 par value per share (10,000,000 shares authorized, 0 and 413,388 issued and outstanding as of December 31, 2012 and 2011, respectively, aggregate liquidation value of $0 and $8,267,760 at December 31, 2012 and 2011, respectively)	0	413
Common stock, $0.001 par value per share (500,000,000 shares authorized, 25,820,738 and 5,061,399 shares issued and outstanding at December 31, 2012 and 2011, respectively)	25,821	5,061
Contingently issuable shares	6	6
Additional paid-in capital	34,534,805	10,472,115
Treasury stock, at cost, 13,526 and 0 shares at December 31, 2012 and 2011, respectively	(84,538)	0
Deficit accumulated in the development stage	(18,925,793)	(853,074)
Total stockholder's equity	15,550,301	9,624,521
Non-controlling interest in subsidiary	0	11,681
Total equity	15,550,301	9,636,202
Total liabilities and equity	$ 22,074,037	$ 14,537,358

Consolidated Balance Sheets [Parenthetical] - USD ($)	Dec. 31, 2012	Dec. 31, 2011
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferredstock, shares issued	0	413,388
Preferred stock, shares outstanding	0	413,388
Preferred Stock, Liquidation Preference Per Share (in dollars)	$ 0	$ 8,267,760
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common stock, shares issued	25,820,738	5,061,399
Common stock, shares outstanding	25,820,738	5,061,399
Treasury stock	13,526	0

Consolidated Statements of Operations - USD ($)	12 Months Ended		13 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
License revenue	$ 19,048	$ 0	$ 19,048
Costs and expenses:
Noncash stock expense associated with in-licensing agreement	16,578,000	297,000	16,875,000
Noncash compensation	455,809	0	455,809
Other research and development	3,994,182	30,283	4,024,465
Total research and development	21,027,991	327,283	21,355,274
General and administrative:
Noncash compensation	2,966,373	86,494	3,052,867
Other general and administrative	1,815,083	468,197	2,283,280
Total general and administrative	4,781,456	554,691	5,336,147
Impairment of in-process research and development	1,104,700	0	1,104,700
Total costs and expenses	26,914,147	881,974	27,796,121
Operating loss	(26,895,099)	(881,974)	(27,777,073)
Other (income) expense:
Interest income	(15,787)	0	(15,787)
Other income	(272,232)	0	(272,232)
Interest expense	905,744	7,097	912,841
Change in fair value of notes payable	(1,659,872)	0	(1,659,872)
Total other (income) expense	(1,042,147)	7,097	(1,035,050)
Loss before income taxes	(25,852,952)	(889,071)	(26,742,023)
Income taxes	330,000	0	330,000
Consolidated net loss	(26,182,952)	(889,071)	(27,072,023)
Net loss attributable to non-controlling interest	(8,110,233)	(35,997)	(8,146,230)
Net loss attributable to TG Therapeutics, Inc. and Subsidiaries	$ (18,072,719)	$ (853,074)	$ (18,925,793)
Basic and diluted net loss per common share (in dollars per share)	$ (1.38)	$ (0.44)
Weighted average shares used in computing basic and diluted net loss per common share (in shares)	13,113,758	1,926,198

Consolidated Statements of Equity - 12 months ended Dec. 31, 2012 - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Contingently Issuable Shares [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] Restricted Preferred Stock [Member]	Additional Paid-In Capital [Member] Restricted Common Stock [Member]	Treasury Stock [Member]	Accumulated Deficit During Development Stage [Member]	Non-Controlling Interest In Subsidiary [Member]	Total	Restricted Preferred Stock [Member]	Restricted Common Stock [Member]
Balance at Dec. 31, 2011	$ 413	$ 5,061	$ 6	$ 10,472,115				$ (853,074)	$ 11,681	$ 9,636,202
Balance (in shares) at Dec. 31, 2011	413,388	5,061,399
Issuance of restricted stock		$ 5,902		(5,902)						0
Issuance of restricted stock (in shares)		5,901,743
Stock issued, net of expenses	$ 696			12,180,710						12,181,406
Stock issued, net of expenses (in shares)	695,428
Compensation in respect of restricted stock granted to employees, directors and consultants					$ 188,509	$ 3,233,674					$ 188,509	$ 3,233,674
Shares issued in subsidiary to non-controlling interest in connection with in-licensing agreement									16,578,000	16,578,000
Conversion of preferred stock to common stock in conjunction with reverse stock split	$ (1,109)	$ 9,858		(8,749)						0
Conversion of preferred stock to common stock in conjunction with reverse stock split (in shares)	(1,108,816)	9,857,596
Non-controlling interest subsidiary shares exchanged for shares in TG Therapeutics, Inc.		$ 5,000		8,474,448					(8,479,448)	0
Non-controlling interest subsidiary shares exchanged for shares in TG Therapeutics, Inc. (in shares)		5,000,000
Surrender of common stock for tax withholding							$ (84,538)			(84,538)
Surrender of common stock for tax withholding (in shares)							13,526
Net loss								(18,072,719)	(8,110,233)	(26,182,952)
Balance at Dec. 31, 2012	$ 0	$ 25,821	$ 6	$ 34,534,805			$ (84,538)	$ (18,925,793)	$ 0	$ 15,550,301
Balance (in shares) at Dec. 31, 2012	0	25,820,738					13,526

Consolidated Statements of Equity [Parenthetical] - $ / shares	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Exchange For License Option [Member]
Fair Value Per Share Issued		$ 2.25
Preferred Stock [Member]
Preferred Stock Issued	$ 20
Common Stock [Member]
Fair Value Per Share Issued		$ 2.25

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended		13 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES
Consolidated net loss	$ (26,182,952)	$ (889,071)	$ (27,072,023)
Adjustments to reconcile consolidated net loss to cash used in operating activities:
Stock compensation expense	3,422,182	86,494	3,508,676
Noncash stock expense associated with in-licensing agreement	16,578,000	297,000	16,875,000
Impairment of in-process research and development	1,104,700	0	1,104,700
Depreciation	235	0	235
Change in fair value and accrued interest of notes payable	(815,699)	0	(815,699)
Changes in assets and liabilities, net of effects of acquisition:
(Increase) decrease in other current assets	(1,932,710)	3,593	(1,929,117)
Increase in accounts payable and accrued expenses	595,757	408,310	1,004,067
Increase in interest payable	61,571	7,097	68,668
Increase in deferred revenue	1,980,952	0	1,980,952
Net cash used in operating activities	(5,187,964)	(86,577)	(5,274,541)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property, plant and equipment	(1,399)	0	(1,399)
Cash acquired in connection with acquisition	0	10,386	10,386
Net cash (used in) provided by investing activities	(1,399)	10,386	8,987
CASH FLOWS FROM FINANCING ACTIVITIES
Payments of short-term loans	(200,001)	0	(200,001)
Proceeds from sale of common stock, net	0	9,824,682	9,824,682
Proceeds from sale of preferred stock, net	12,257,309	0	12,257,309
Offering costs paid	(75,903)	0	(75,903)
Purchase of treasury stock	(84,538)	0	(84,538)
Net cash provided by financing activities	11,896,867	9,824,682	21,721,549
NET INCREASE IN CASH AND CASH EQUIVALENTS	6,707,504	9,748,491	16,455,955
Cash and cash equivalents at beginning of year	9,748,491	0	0
CASH AND CASH EQUIVALENTS AT END OF YEAR	16,455,995	9,748,491	16,455,995
NONCASH TRANSACTIONS
Conversion of notes payable to preferred stock	0	55,271	55,271
Accrued financing costs	$ 0	$ 61,138	$ 61,138

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2012

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Significant Accounting Policies [Text Block]

NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

DESCRIPTION OF BUSINESS

We are a biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding their research and development and eventually either out-licensing or bringing the technologies to market. Currently, the Company is developing therapies targeting hematological malignancies.TG-1101 (ublituximab), is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. We are also developing TGR-1202, an orally available PI3K delta inhibitor. We also hold the development rights to AST-726, a nasally delivered product for the treatment of Vitamin B₁₂ deficiency.

Exchange Transaction with TG Therapeutics, Inc. and its majority shareholders

On December 29, 2011, the Company entered into and consummated an Exchange Transaction Agreement with Opus Point Partners, LLC (“Opus”) and TG Biologics, Inc. (formerly known as TG Therapeutics, Inc.) (“TG Bio”) (the “Agreement”). Under the Agreement, Opus exchanged (the “Exchange Transaction”) its shares of common stock in TG Bio (“TG Bio Common Stock”) for shares of Series A preferred stock in the Company (“Company Preferred Stock”). In accordance with the terms of the Agreement, 95% of the holders of common stock of TG Bio (one (1) minority shareholder of TG Bio holding in aggregate 132,000 shares of common stock of TG Bio did not participate) surrendered their TG Bio common stock. The Agreement caused the Company to issue to TG Bio’s shareholders 281,250 shares of Company Preferred Stock. Each share of Company Preferred Stock was convertible into 8.89 shares of the Common Stock provided that such conversion rights were subject to sufficient available authorized shares of Common Stock. In connection with the reverse stock split effected by the Company on April 30, 2012 (as discussed below), all shares of preferred stock issued in connection with the Agreement were converted to Common Stock. The Company Preferred Stock issued in connection with the Agreement provided the former TG Bio shareholders with direct and/or indirect ownership of approximately 95% of the Company’s outstanding Company Common Stock immediately following the consummation of the transaction.

Since the stockholders of TG Bio received the majority of the voting shares of the Company, the merger was accounted for as a reverse acquisition whereby TG Bio was the accounting acquirer (legal acquiree) and the Company was the accounting acquiree (legal acquirer) under the acquisition method of accounting. TG Bio was incorporated in Delaware in November 2010, but did not commence operations until April 2011.

The filings with the Securities and Exchange Commission (the “SEC”) include the historical financial results of TG Bio and will hereafter collectively be referred to as the Company.

On April 30, 2012, the Company filed a Certificate of Amendment to its Certificate of Incorporation to change its name from Manhattan Pharmaceuticals, Inc. (“Manhattan”) to TG Therapeutics, Inc. In conjunction with this change, the subsidiary formerly named TG Therapeutics, Inc. filed a Certificate of Amendment changing its name to TG Biologics, Inc.

CORRECTION OF AN IMMATERIAL ERROR

The Company has identified certain immaterial errors in its previously issued consolidated financial statements for the year ended December 31, 2011. In connection with the Exchange Transaction (see description above), a valuation using the guidance in the accounting literature for business combinations was performed to determine the fair value of the assets acquired and liabilities assumed. The Company has determined that certain methodologies and assumptions utilized in this valuation were incorrect. As a result of this, the Company has recorded an adjustment to previously reported in-process research and development, goodwill, and notes payable, less current portion, at fair value, at December 31, 2011 as follows:

In-process research and development decreased from $5,441,839 to $3,902,300

Goodwill increased from $629,752 to $799,391

Notes payable, less current portion, at fair value decreased from $4,664,697 to $3,294,797

The net effect of this adjustment is a decrease to total assets and liabilities, as previously reported, of $1,369,900.

The adjustment was recorded as of December 31, 2011 and has no effect on the statement of operations or statement of equity for any period. The Company assessed the impact of this adjustment under the provisions of SEC Staff Accounting Bulletin Nos. 99 and 108 and determined the impact of the errors to be immaterial to the financial statements. The accompanying consolidated balance sheet as of December 31, 2011 reflects the corrections of the aforementioned immaterial errors.

LIQUIDITY AND CAPITAL RESOURCES

We have incurred operating losses since our inception, and expect to continue to incur operating losses for the foreseeable future and may never become profitable. As of December 31, 2012, we have an accumulated deficit of $18,925,793.

Our primary source of cash has been proceeds from the private placement of equity securities. We have not yet commercialized any of our drug candidates and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become profitable. Our ability to achieve profitability depends on a number of factors, including our ability to obtain regulatory approval for our drug candidates, successfully complete any post-approval regulatory obligations and successfully commercialize our drug candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues from our drug candidates.

As of December 31, 2012, we had $16,455,995 in cash and cash equivalents. We currently anticipate that our cash and cash equivalents to be sufficient to fund our anticipated operating cash requirements for approximately 18 months from December 31, 2012. The actual amount of cash that we will need to operate is subject to many factors, including, but not limited to, the timing, design and conduct of clinical trials for our drug candidates. We are dependent upon significant future financing to provide the cash necessary to execute our current operations, including the commercialization of any of our drug candidates.

Our common stock is quoted on the OTC Bulletin Boardand trades under the symbol “TGTX.”

REVERSE STOCK SPLIT

On April 30, 2012, the Company effected a reverse split of its Common Stock at a ratio of 56.25 for 1, pursuant to a previously obtained stockholder authorization. All share amounts and per share prices in this Annual Report on Form 10-K have been retroactively adjusted to reflect the effect of our reverse stock split, on a fifty-six and one quarter (56.25) for one (1) basis, unless otherwise indicated. The exercise price for all stock options and warrants and the conversion price for convertible securities in the accompanying consolidated financial statements have been adjusted to reflect the reverse stock split by multiplying the original exercise or conversion price by fifty-six and one quarter (56.25).

2011 MANAGEMENT CHANGES

In connection with the Exchange Transaction with TG Therapeutics, Inc., effective December 29, 2011, Douglas Abel, David C. Shimko and Richard Steinhart resigned from their positions on the Board of Directors of the Company. Michael McGuinness resigned both his seat as a director and as an officer of the Company, effective December 29, 2011.

Effective December 29, 2011, Michael S. Weiss was appointed Executive Chairman, Interim Chief Executive Officer and President of the Company. In connection with the appointment, the Company assumed Mr. Weiss’ employment agreement with TG, effective November 1, 2011, under which Mr. Weiss is to serve as the Company’s Executive Chairman, Interim Chief Executive Officer and President until such employment is terminated pursuant to the terms of the agreement.

In connection with the Exchange Transaction and the appointment of Mr. Weiss to his position, the Company issued replacement awards and granted 112,500 shares of Series A Preferred Stock, to Mr. Weiss on December 29, 2011. Each share of Series A Preferred Stock was convertible into 8.89 shares of the Common Stock provided that such conversion rights were subject to sufficient available authorized shares of Common Stock. In connection with the reverse stock split effected by the Company on April 30, 2012 (as discussed above), all shares of preferred stock issued in connection with the Agreement were converted to Common Stock.

Under the terms of his employment agreement, on an annual basis, the Company will also grant Mr. Weiss a number of shares of restricted common stock equal to 1.25% of the shares of Common Stock outstanding on the date of grant on a fully-diluted basis. Each of these annual grants of restricted stock will vest and become non-forfeitable as to 25% of the shares on the first anniversary of the respective date of grant, as to 25% of the shares on the second anniversary of the respective date of grant and as to 50% of the shares on the date that the “market capitalization” (as defined in the employment agreement) is $100 million greater than the market capitalization on the respective date of grant, provided that Mr. Weiss remains an employee, director and/or consultant of the Company through each vesting date.

Effective December 29, 2011, Sean A. Power was appointed Chief Financial Officer, Treasurer and Secretary of the Company. In connection with the appointment, the Company assumed Mr. Power’s employment agreement with TG, effective November 1, 2011, under which Mr. Power is to serve as the Company’s Chief Financial Officer, Treasurer and Secretary until such employment is terminated pursuant to the terms of the agreement.

In connection with the Exchange Transaction and the appointment of Mr. Power to his position, the Company issued replacement awards and granted 16,875 shares of Series A Preferred Stock, to Mr. Power on December 29, 2011. Each share of Series A Preferred Stock was convertible into 8.89 shares of the Common Stock provided that such conversion rights were subject to sufficient available authorized shares of Common Stock. In connection with the reverse stock split effected by the Company on April 30, 2012 (as discussed above), all shares of preferred stock issued in connection with the Agreement were converted to Common Stock.

The Company will grant Mr. Power a number of shares of restricted common stock of the Company as determined by the CEO and board. Each of these annual grants of restricted stock will be subject to vesting terms, which will be determined at the time of grant by the CEO and Board.

RECENTLY ISSUED ACCOUNTING STANDARDS

In February 2013, the Financial Accounting Standards Board (“FASB”) issued amendments to the accounting guidance for presentation of comprehensive income to improve the reporting of reclassifications out of accumulated other comprehensive income. The amendments do not change the current requirements for reporting net income or other comprehensive income, but do require an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the statement where the net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under GAAP to be reclassified to net income in its entirety in the same reporting period. For other amounts that are not required under GAAP to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures required under GAAP that provide additional detail about these amounts. These amendments are effective prospectively for reporting periods beginning after December 15, 2012. The Company does not believe the adoption of this guidance will have a material impact on the consolidated financial statements.

Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to the consolidated financial statements of the Company.

BASIS OF PRESENTATION

The Company has generated limited revenue from its operations and, accordingly, the financial statements have been prepared in accordance with the provisions of accounting and reporting for Development Stage Enterprises.

USE OF ESTIMATES

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. Actual results could differ from those estimates. Such differences could be material to the financial statements.

CASH AND CASH EQUIVALENTS

We treat liquid investments with original maturities of less than three months when purchased as cash and cash equivalents.

REVENUE RECOGNITION

We recognize license revenue in accordance with the revenue recognition guidance of the FASB Accounting Standards Codification, or Codification. We analyze each element of our licensing agreement to determine the appropriate revenue recognition. The terms of the license agreement may include payments to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings process and no further performance obligation exists under the contract. We recognize milestone payments as revenue upon the achievement of specified milestones only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract.

RESEARCH AND DEVELOPMENT COSTS

Generally, research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered or the related services are performed, subject to an assessment of recoverability. We make estimates of costs incurred in relation to external clinical research organizations, or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued balance and expense in any accounting period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.

IN-PROCESS RESEARCH AND DEVELOPMENT

All acquired research and development projects are recorded at their fair value as of the date acquisition. The fair values are assessed as of the balance sheet date to ascertain if there has been any impairment of the recorded value. If there is an impairment, the asset is written down to its current fair value by the recording of an expense. Impairment is tested on an annual basis, and consists of a comparison of the fair value of the in-process research and development with its carrying amount.

INCOME TAXES

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. If the likelihood of realizing the deferred tax assets or liability is less than “more likely than not,” a valuation allowance is then created.

We, and our subsidiaries, file income tax returns in the U.S. Federal jurisdiction and in various states. We have tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination.

We recognize interest and penalties related to uncertain income tax positions in income tax expense.

STOCK - BASED COMPENSATION

We recognize all share-based payments to employees and to non-employee directors as compensation for service on our board of directors as compensation expense in the consolidated financial statements based on the fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

For share-based payments to consultants and other third-parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date.

BASIC AND DILUTED NET (LOSS) INCOME PER COMMON SHARE

Basic net income (loss) per common share is calculated by dividing net income (loss) applicable to common shares by the weighted-average number of common shares outstanding for the period. Diluted net loss per common share is the same as basic net income (loss) per common share, since potentially dilutive securities from stock options, stock warrants and convertible preferred stock would have an antidilutive effect either because the Company incurred a net loss during the period presented or because such potentially dilutive securities were out of the money and the Company realized net income during the period presented. The amounts of potentially dilutive securities excluded from the calculation were 10,746,837 and 5,320,173 at December 31, 2012 and 2011, respectively. During the years ended December 31, 2012 and 2011 the Company incurred a net loss, therefore, all of the dilutive securities are excluded from the computation of diluted earnings per share.

LONG LIVED ASSETS AND GOODWILL

Long lived assets are reviewed for an impairment loss when circumstances indicate that the carrying value of long-lived tangible and intangible assets with finite lives may not be recoverable. Management’s policy in determining whether an impairment indicator exists, a triggering event, comprises measurable operating performance criteria as well as qualitative measures. If an analysis is necessitated by the occurrence of a triggering event, we make certain assumptions in determining the impairment amount. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized.

Goodwill is reviewed for impairment annually, or when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process. The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying value of the reporting unit is greater than fair value, the unit’s goodwill may be impaired, and the second step must be completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting unit’s goodwill is compared with the carrying amount of the unit’s goodwill. If the carrying amount is greater than the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. We will continue to perform impairment tests annually, at December 31, and whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable.

- Definition

The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.

+ References + Details

CASH AND CASH EQUIVALENTS

12 Months Ended

Dec. 31, 2012

Cash and Cash Equivalents [Abstract]

Cash and Cash Equivalents Disclosure [Text Block]

NOTE 2 – CASH AND CASH EQUIVALENTS

	December 31, 2012		December 31, 2011

Checking and bank deposits	$	16,455,995	$	9,748,491
Total	$	16,455,995	$	9,748,491

- Definition

The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 6.H.3)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13728-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7
-Footnote 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section H
-Subsection 3

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 8, 9, 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

FAIR VALUE MEASUREMENTS

12 Months Ended

Dec. 31, 2012

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

NOTE 3 – FAIR VALUE MEASUREMENTS

We measure certain financial assets and liabilities at fair value on a recurring basis in the financial statements. The hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:

Level 1 – quoted prices in active markets for identical assets and liabilities;

Level 2 – inputs other than Level 1 quoted prices that are directly or indirectly observable; and

Level 3 – unobservable inputs that are not corroborated by market data.

As of December 31, 2012 and 2011, the fair values of cash and cash equivalents, and notes and interest payable, current portion approximate their carrying value.

Upon the merger between Manhattan and Ariston Pharmaceuticals, Inc. (“Ariston”) in March 2010, Ariston issued $15,452,793 of five-year 5% notes payable (the “5% Notes”) in satisfaction of several note payable issuances. The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into Common Stock at the conversion price of $1,125 per share. Ariston agreed to make quarterly payments on the 5% Notes equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston’s product candidates, AST-726 and AST-915. The Company has no obligations under the 5% Notes aside from a) 50% of the net product cash flows from Ariston’s product candidates, if any, payable to noteholders; and b) the conversion feature, discussed above.

In connection with the Exchange Transaction in December 2011, the Company performed a valuation of the assets and liabilities of Manhattan immediately prior to the transaction. The cumulative liability including accrued and unpaid interest of these notes was approximately $16,876,000 immediately prior to the Exchange Transaction, and $17,727,000 and $16,883,000 at December 31, 2012 and 2011, respectively. As these notes payable are tied directly to net product cash flows derived from the preexisting products of the Company, this note and accrued interest was recorded at fair value of $3,287,700 as of the date of the Exchange Transaction. No payments have been made on these notes as of December 31, 2012.

We elected the fair value option for valuing the 5% Notes upon the completion of the reverse merger with TG Bio, as discussed above. The Company elected the fair value option in order to reflect in our financial statements the assumptions that market participants use in evaluating these financial instruments.

The valuation method used to estimate the 5% Notes’ fair value was a discounted cash flow model, where the expected cash flows of AST-726 and AST-915 are discounted to the present using a yield that incorporates compensation for the probability of success in clinical development and marketing, among other factors. The discount rate used in this discounted cash flow model approximated 20% at December 31, 2012 and 2011. The assumptions, assessments and projections of future revenues are subject to uncertainties, are difficult to predict and require significant judgment. The use of different assumptions, applying different judgment to inherently subjective matters and changes in future market conditions could result in significantly different estimates of fair value and the differences could be material to our consolidated financial statements.

The Company’s financial liabilities measured at fair value on a recurring basis as of December 31, 2012 and 2011 were as follows:

	Financial liabilities at fair value as of December 31, 2012
	Level 1		Level 2		Level 3		Total

5% Notes	$	--	$	--	$	2,479,098	$	2,479,098
Totals	$	--	$	--	$	2,479,098	$	2,479,098

	Financial liabilities at fair value as of December 31, 2011
	Level 1		Level 2		Level 3		Total

5% Notes	$	--	$	--	$	3,294,797	$	3,294,797
Totals	$	--	$	--	$	3,294,797	$	3,294,797

The Level 3 amounts above represent the fair value of the 5% Notes and related accrued interest.

The following table summarizes the changes in Level 3 instruments for the years ended December 31, 2011 and 2012:

Balance at January 1, 2011	$	--
Transfer into Level 3		3,287,700
Interest accrued on face value of 5% Notes		7,097
Change in fair value of Level 3 liabilities		--
Balance at December 31, 2011		3,294,797
Interest accrued on face value of 5% Notes		844,173
Change in fair value of Level 3 liabilities		(1,659,872)
Balance at December 31, 2012	$	2,479,098

The change in the fair value of the Level 3 liabilities is reported in other (income) expense in the accompanying consolidated statements of operations.

Nonrecurring Fair Value Measurements

The Company’s assets measured at fair value on a nonrecurring basis as of December 31, 2012 were as follows:

	Fair value measurements as of December 31, 2012
	Level 1		Level 2		Level 3		Total impairment charge for the year ended December 31, 2012
Assets:
In-process research and development	$	--	$	--	$	2,797,600	$	(1,104,700	)
Total	$	--	$	--	$	2,797,600	$	(1,104,700	)

As a result of market changes affecting the commercial potential for the Ariston in-process research and development assets (AST-726 and AST-915), the Company determined that the asset's carrying value was no longer fully recoverable. Accordingly, during the year ended December 31, 2012, we recorded a non-cash impairment charge of approximately $1,104,700, which was recorded as impairment of in-process research and development in our consolidated statements of operations. The fair value of this asset was determined using a discounted cash flow model, where the expected cash flows of the Ariston assets are discounted to the present using a yield that incorporates compensation for the probability of success in clinical development and marketing, among other factors. This fair value measurement technique is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. Changes in the market or any of the assumptions used in determining the fair value of this asset may result in a further reduction to its estimated fair value and could result in additional and potentially full future impairment charges. Also contributing to the impairment charge was the Company’s decision during the year ended December 31, 2012 to discontinue future development activities for AST-915, following the analysis from a Phase I dose escalation trial, in which AST-915 failed to meet its primary efficacy endpoint.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

ACQUISITION

12 Months Ended

Dec. 31, 2012

Business Combinations [Abstract]

Business Combination Disclosure [Text Block]

NOTE 4 – ACQUISITION

On December 29, 2011, the Company completed a reverse acquisition of privately held TG Bio, a Delaware Corporation. The acquisition was effected pursuant to an Exchange Transaction Agreement (the “Agreement”) dated December 29, 2011 by and among the Company, TG Bio and Opus, the largest shareholder of TG Bio. In accordance with the terms of the Agreement, 95% of the holders of common stock of TG Bio (one (1) minority shareholder of TG Bio holding in aggregate 132,000 shares of common stock of TG Bio did not participate) surrendered their TG Bio common stock. The Agreement caused the Company to issue to TG Bio’s shareholders 281,250 shares of Company Preferred Stock. Each share of Company Preferred Stock was convertible into 8.89 shares of the Common Stock provided that such conversion rights were subject to sufficient available authorized shares of Common Stock. In connection with the reverse stock split effected by the Company on April 30, 2012 (as discussed above), all shares of preferred stock issued in connection with the Agreement were converted to Common Stock. The Company Preferred Stock issued in connection with the Agreement provided the former TG Bio shareholders with direct and/or indirect ownership of approximately 95% of the Company’s outstanding Company Common Stock immediately following the consummation of the transaction.

The shares of Common Stock issued upon the conversion of the Company Preferred Stock are not registered for resale and, therefore, shall remain subject to the rights and restrictions of Rule 144 under the Securities Act of 1933, as amended.

Based on fair value of the Company’s Common Stock of $2.25 per share at December 29, 2011, the purchase price was $295,933, plus the fair value of restricted stock assumed of $82,305. In connection with the Exchange Transaction, the Company incurred $231,580 of acquisition related costs.

A summary of the purchase price calculation is as follows:

Number of shares of Manhattan common stock outstanding at the time of the transaction		131,526
Multiplied by Manhattan’s fair value of the Common Stock	$	2.25	$	295,933
Fair value of restricted stock assumed				82,305
Total purchase price			$	378,238

The purchase price has been allocated as follows based on the fair values of the assets and liabilities acquired:

Cash and cash equivalents	$	10,386
Other assets		90,770
In-process research and development acquired		3,902,300
Total identifiable assets		4,003,456
Accounts payable and accrued expenses		197,191
Notes payable (ICON and Swiss Pharma)		939,718
5% notes payable and accrued interest		3,287,700
Total identifiable liabilities		4,424,609
Net identifiable assets (liabilities)		(421,153	)
Goodwill		799,391
Total	$	378,238

The fair value of certain identifiable intangible assets was determined using the income approach. This method starts with a forecast of the expected future net cash flows. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk of achieving the asset’s projected cash flows. The present value of the estimated cash flows are then added to the present value equivalent of the residual value of the asset, if any, at the end of the discrete projection period to estimate the fair value.

The valuations are based on information that is available as of the acquisition date and the expectations and assumptions that have been deemed reasonable by our management. No assurance can be given, however, that the underlying assumptions or events associated with such assets will occur as projected. For these reasons, among others, the actual results may vary from the projected results.

The following supplemental pro forma information for the year ended December 31, 2011 presents the financial results as if the transaction had occurred on January 1, 2011. This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2011, nor are they indicative of future results.

	2011
Revenue	$	--
Net loss	$	(818,279	)
Basic and diluted loss per common share	$	(0.31	)

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1383-128463

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 88-16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph F4
-Subparagraph e
-Appendix F

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51, 52
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 67-73
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

STOCKHOLDERS' EQUITY

12 Months Ended

Dec. 31, 2012

Stockholders' Equity Note [Abstract]

Stockholders Equity Note Disclosure [Text Block]

NOTE 5 – STOCKHOLDERS’ EQUITY

Preferred Stock

Our amended and restated certificate of incorporation authorizes the issuance of up to 10,000,000 shares of preferred stock, $0.001 par value, with rights senior to those of our common stock, issuable in one or more series. Upon issuance, the Company can determine the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock.

There were 413,388 shares of preferred stock outstanding as of December 31, 2011. In connection with the Exchange Transaction with TG Therapeutics, Inc., on December 29, 2011, the Company filed a Certificate of Designation with respect to its Series A Preferred Stock with the Secretary of State of the State of Delaware. The Company Preferred Stock ranks senior to the Company Common Stock with regard to dividend rights, and has a liquidation preference of $20 per share over the Company Common Stock and any other junior securities. The Company Preferred Stock is automatically convertible into 500 shares of Company Common Stock provided that prior to conversion, the Company has sufficient authorized Company Common Stock to effect such conversion. In conjunction with the reverse split effected on April 30, 2012 (as discussed in Note 1), all outstanding Company Preferred Stock automatically converted to 9,857,596 shares of Common Stock as of that date.

Common Stock

Our amended and restated certificate of incorporation authorizes the issuance of up to 500,000,000 shares of $0.001 par value common stock.

On December 30, 2011, we completed the first closing of the private placement of our securities, issuing 4,929,523 shares of Common Stock at a price per share of $2.25 for total gross proceeds, before placement commissions and expenses, of $11,091,425 (the “2011 Equity PIPE”). Investors also received warrants to purchase 1,232,381 shares of Common Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years.

In 2012, we completed two additional closings of the 2011 Equity PIPE. These closings were held on January 31, 2012, and February 24, 2012. In these closings, the Company issued 695,428 shares of our Company Preferred Stock at a price per share of $20.00 for total gross proceeds, before placement commissions and expenses, of $13,908,560. Each share of Company Preferred Stock was convertible into 8.89 shares of Common Stock; provided that such conversion rights were subject to sufficient available authorized shares of Common Stock.In connection with the reverse stock split effected by the Company on April 30, 2012, all shares of Preferred Stock issued in the 2011 Equity PIPE were converted to Common Stock. Investors also received warrants to purchase 1,545,396 shares of Common Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years. The shares of Company Preferred Stock and warrants sold in these closings were offered and sold to accredited investors, including members of management, without registration under the Securities Act, or state securities laws, in reliance on the exemptions provided by Section 4(2) of the Securities Act, and Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. Accordingly, the securities issued in the offering have not been registered under the Securities Act, and until so registered, these securities may not be offered or sold in the United States absent registration or availability of an applicable exemption from registration. The placement agent received cash commissions equal to 10% of the gross proceeds of the offering, five-year warrants to purchase shares of the Company’s stock equal to 10% of shares sold in the offering, and a non-accountable expense allowance equal to two percent of the gross proceeds of the offering for their expenses.

Treasury Stock

On May 17, 2012, our Chief Financial Officer surrendered to the Company 13,526 shares of common stock in order to satisfy his tax withholding obligation upon the vesting of 37,500 shares of restricted stock. The 13,526 shares of common stock are being held by the Company in Treasury, at a cost of approximately $85,000, representing the fair market value on the date the shares were surrendered.

Equity Incentive Plans

We have in effect the following stock option and incentive plans.

a. In July 1995, the Company established the 1995 Stock Option Plan (the “1995 Plan”), which provided for the granting of options to purchase up to 2,600 shares of the Company’s common stock to officers, directors, employees and consultants. The 1995 Plan was amended several times to increase the number of shares reserved for stock option grants. In June 2005, the 1995 Plan expired and no further options can be granted. At December 31, 2012, options to purchase 313 shares were outstanding and no shares were reserved for future stock option grants under the 1995 Plan.

b. The Company has shareholder-approved incentive stock option plans for employees under which it has granted non-qualified and incentive stock options. At December 31, 2012, 5,333 shares were authorized for issuance. The options have a maximum term of 10 years and vest over a period determined by the Company’s Board of Directors (generally 3 years) and are issued at an exercise price equal to or greater than the fair market value of the shares at the date of grant. At December 31, 2012, options to purchase 591 shares were outstanding, 10 shares of common stock were issued and there were 4,732 shares reserved for future grants under the Plan.

c. In May 2012, the Company established the TG Therapeutics, Inc. Amended and Restated 2012 Incentive Plan (“2012 Incentive Plan”). Under the 2012 Incentive Plan, the compensation committee of the Company’s board of directors is authorized to grant stock-based awards to directors, consultants, employees and officers. The 2012 Incentive Plan authorizes grants to purchase up to 6,000,000 shares of authorized but unissued common stock. As of December 31, 2012, options to purchase 46,000 shares were outstanding and up to an additional 2,052,257 shares may be issued under the 2012 Incentive Plan.

Stock Options

The following table summarizes stock option activity for the years ended December 31, 2012 and 2011:

	Number of shares			Weighted- average exercise price		Weighted- average Contractual Term		Aggregate Intrinsic Value
						(in years)
Outstanding at January 1, 2011		--			--
Assumed in Exchange Transaction		4,143		$	1,375.18		5.60
Granted		--			--
Exercised		--			--
Forfeited		(364	)		197.34
Expired		(400	)		2,951.12
Outstanding at December 31, 2011		3,379			1,315.62		6.39	$	--
Granted		46,000			4.40
Exercised		--			--
Forfeited		(2,475	)		720.45
Expired		--			--
Outstanding at December 31, 2012		46,904		$	61.08		9.44	$	--

Vested and expected to vest at December 31, 2012		904		$	2,945.09		1.73	$	--
Exercisable at December 31, 2012		898		$	2,963.46		1.70	$	--

As of December 31, 2012, the total compensation cost related to unvested time-based option awards not yet recognized is less than $1,000. The weighted average period over which it is expected to be recognized is approximately 3 months. This amount does not include, as of December 31, 2012, 46,000 non-employee options outstanding which are milestone-based and vest upon certain corporate milestones. Stock-based compensation will be measured and recorded if and when a milestone occurs.

Restricted Stock- Preferred

Certain employees had been awarded restricted preferred stock. The restricted stock vesting consisted of milestone and time-based vesting. The following table summarizes restricted share activity for the years ended December 31, 2012 and 2011:

	Number of Shares Restricted Series A Preferred Stock⁽¹⁾			Weighted Average Grant Date Fair Value
Outstanding at January 1, 2011		--		$	--
Granted		129,375			20.00
Vested		--			--
Forfeited		--			--
Outstanding at December 31, 2011		129,375			20.00
Granted		--			--
Vested		--			--
Forfeited		--			--
Conversion to restricted common stock		(129,375	)		20.00
Outstanding at December 31, 2012		--		$	--

⁽¹⁾The restricted preferred stock listed in the table above was granted in connection with the Exchange Transaction to certain executives as discussed above. Each share of preferred stock was convertible into 8.89 shares of the Company’s Common Stock. In conjunction with the reverse split effected on April 30, 2012 (as discussed in Note 1), all outstanding restricted Preferred Stock automatically converted to 1,150,000 shares of restricted Common Stock as of that date.

Restricted Stock- Common

Certain employees, directors and consultants have been awarded restricted Company Common Stock. The restricted stock vesting consists of milestone and time-based vesting. The following table summarizes restricted share activity for the years ended December 31, 2012 and 2011:

	Number of Shares			Weighted Average Grant Date Fair Value
Outstanding at January 1, 2011		--		$	--
Granted		--			--
Vested		--			--
Forfeited		--			--
Outstanding at December 31, 2011		--			--
Converted preferred stock		1,150,000			2.25
Granted		5,901,743			4.77
Vested		(437,500	)		2.25
Forfeited		--			--
Outstanding at December 31, 2012		6,614,243		$	4.49

Total expense associated with restricted stock grants (both common and preferred) was $3,422,182 and $86,494 during the years ended December 31, 2012 and 2011, respectively. As of December 31, 2012, there was approximately $8,941,000 of total unrecognized compensation cost related to non-vested time based restricted stock, which is expected to be recognized over a weighted-average period of 2.8 years. This amount does not include, as of December 31, 2012, 2,092,500 shares of restricted stock outstanding which are milestone-based and vest upon certain corporate milestones; and 2,580,000 shares of restricted stock outstanding issued to non-employees (see Note 10 – Related Party Transactions for additional information). Milestone based non-cash compensation expense will be measured and recorded if and when a milestone occurs.

Warrants

The following table summarizes warrant activity for the years ended December 31, 2012 and 2011:

	Warrants			Weighted- average exercise price		Aggregate Intrinsic Value
Outstanding at January 1, 2011		--		$	--
Assumed in Exchange Transaction		393,437			14.74
Issued		1,232,474			2.25
Exercised		--			--
Expired		--			--
Outstanding at December 31, 2011		1,625,911			5.27	$	--
Issued		5,156,599			1.21
Exercised		--			--
Expired		(1,503	)		2,739.75
Outstanding at December 31, 2012		6,781,007		$	1.58	$	14,563,539

As discussed above, as part of the 2011 Equity PIPE, we issued warrants to purchase up to 2,777,962 shares of our common stock, none of which have been exercised as of December 31, 2012. The warrants have an exercise price of $2.25 per warrant share. In addition, we issued to the placement agent in the transaction warrants to purchase up to 1,111,111 shares of our common stock at an exercise price of $2.48 per warrant share, none of which have been exercised as of December 31, 2012.

In connection with the Securities Exchange Agreement between the Company and LFB Group as discussed in Note 8 – License Agreements, we issued LFB Group a warrant to purchase an aggregate of 2,500,000 shares of Company Common Stock at a purchase price of $0.001 per share.

Stock-Based Compensation

The fair value of stock options granted is estimated at the date of grant using the Black-Scholes pricing model. The expected term of options granted is derived from historical data and the expected vesting period. Expected volatility is based on the historical volatility of our common stock. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. We have assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will not be paid for the foreseeable future. The Company did not grant any stock options during the year-ended December 31, 2011.

The following table summarizes stock-based compensation expense information about stock options and restricted stock for the years ended December 31, 2012 and 2011:

	2012		2011

Stock-based compensation expense associated with restricted stock	$	3,422,182	$	86,494
Stock-based compensation expense associated with option grants		--		--
	$	3,422,182	$	86,494

Non-controlling Interest

Accordingly, in connection with the aforementioned Securities Exchange Agreement, TG Bio became a wholly owned subsidiary of the Company. Prior to the execution of the Securities Exchange Agreement LFB Group owned approximately 42.9% of TG Bio. The non-controlling interest in subsidiary balance was approximately $8,479,000 immediately prior to LFB Group exercising their option, which was transferred to equity in connection with the transaction.

NOTES PAYABLE

12 Months Ended

Dec. 31, 2012

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

NOTE 6 – NOTES PAYABLE

The following is a summary of notes payable:

	December 31, 2012						December 31, 2011
	Current portion, net		Non- current portion, net		Total		Current portion, net		Non- current portion, net		Total
Non-interest Bearing Note Payable, Net	$	--	$	-	$	--	$	200,000	$	-	$	200,000
Convertible 5% Notes Payable		-		2,479,098		2,479,098		-		3,294,797		3,294,797
ICON Convertible Note		677,778		-		677,778		677,778		-		677,778
Total	$	677,778	$	2,479,098	$	3,156,876	$	877,778	$	3,294,797	$	4,172,575

We assumed the preceding notes payable as the result of the Exchange Transaction between the Company and TG Therapeutics, Inc. Accordingly, a valuation using the guidance in the accounting literature for business combinations (ASC 805) was performed and these notes have been presented at their fair value on the date of the transaction.

Non-interest Bearing Note Payable

In October 2009, Manhattan entered into a Settlement Agreement and Mutual Release with Swiss Pharma Contract LTD (“Swiss Pharma”) pursuant to which Manhattan agreed to pay Swiss Pharma $200,000 and issue to Swiss Pharma an interest free promissory note due on October 27, 2011 in the principal amount of $250,000 in full satisfaction of a September 5, 2008 arbitration award. In November 2011, Manhattan renegotiated the $250,000 promissory note in which the amount of the promissory note was reduced to $200,000 and the maturity date was extended to February 15, 2012. This amount was paid on February 14, 2012 in full settlement of this note.

Convertible 5% Notes Payable

On March 8, 2010, Manhattan entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Company, Ariston Pharmaceuticals, Inc., a Delaware corporation ("Ariston") and Ariston Merger Corp., a Delaware corporation and wholly-owned subsidiary of the Company (the "Merger Sub"). Pursuant to the terms and conditions set forth in the Merger Agreement, on March 8, 2010, the Merger Sub merged with and into Ariston (the "Merger"), with Ariston being the surviving corporation of the Merger. As a result of the Merger, Ariston became a wholly-owned subsidiary of Manhattan.

The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into Common Stock at the conversion price of $1,125 per share. Ariston agreed to make quarterly payments on the 5% Notes equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston’s product candidates, AST-726 and AST-915. The Company has no obligations under the 5% Notes aside from a) 50% of the net product cash flows from Ariston’s product candidates, if any, payable to noteholders; and b) the conversion feature, discussed above. Interest accrues monthly, is added to principal on an annual basis, every March 8, and is payable at maturity, which is March 8, 2015.

ICON Convertible Note Payable

In connection with the merger with Ariston as discussed above, Ariston satisfied an account payable of $1,275,188 to ICON Clinical Research Limited (“ICON”) through the payment of $275,188 in cash and the issuance of a three-year 5% note payable (the “ICON Note”). The principal was to be repaid in 36 monthly installments of $27,778 commencing in April 2010. Interest was payable monthly in arrears. On March 1, 2011 Ariston entered into an amended and restated convertible promissory note (the “Amended ICON Note”) with ICON. The principal terms of the Amended ICON Note are that monthly payments of principal and interest will be waived for the thirteen month period ended December 31, 2011 (the “Waiver Period”) in exchange for a single payment of $100,000 on March 31, 2011, an increase in the interest on the Amended ICON Note from 5% to 8% per annum during the Waiver Period and a balloon payment on January 31, 2012. The Amended ICON Note is convertible at the option of the holder into the Company’s common stock at the conversion price of $562.50 per share. During the year ended December 31, 2012, the Company recorded $61,571 of interest expense on the Amended ICON Note. As of December 31, 2012 and 2011, the principal amount of the Amended ICON Note was $677,778, of which the entire balance has been classified as current and is reflected as notes payable, current portion, net in the accompanying consolidated balance sheets. Interest payable on the Amended ICON Note was $123,511 and $61,941 as of December 31, 2012 and 2011, respectively, and is reflected as interest payable, current portion, net in the accompanying consolidated balance sheets. This note is currently in default as the Company did not make the balloon payment due on January 31, 2012, or any subsequent payments. The Company is currently attempting to negotiate a settlement or alternative arrangement in satisfaction of this note.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

INCOME TAXES

12 Months Ended

Dec. 31, 2012

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

NOTE 7 – INCOME TAXES

We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. In determining the need for a valuation allowance, management reviews both positive and negative evidence, including current and historical results of operations, future income projections and the overall prospects of our business. Based upon management's assessment of all available evidence, we believe that it is more-likely-than-not that the deferred tax assets will not be realizable; and therefore, a valuation allowance has been established. The valuation allowance for deferred tax assets was approximately $36,271,000 and $29,408,000 as of December 31, 2012 and 2011, respectively.

As of December 31, 2012, we have U.S. net operating loss carryforwards (“NOLs”) of approximately $83,637,000. For income tax purposes, these NOLs will expire in various amounts through 2032. The Tax Reform Act of 1986 contains provisions which limit the ability to utilize net operating loss carryforwards in the case of certain events including significant changes in ownership interests. The Exchange Transaction with TG Bio may have resulted in a “change in ownership” as defined by IRC Section 382 of the Internal Revenue Code of 1986, as amended. Accordingly, a substantial portion of the Company’s NOLs above may be subject to annual limitations in reducing any future year’s taxable income.

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2012 and 2011 are presented below.

	2012			2011
Deferred tax assets (liabilities):
Net operating loss carryforwards	$	32,190,080		$	27,611,000
Research and development credit		1,882,238			1,858,000
Non-cash compensation		3,051,920			1,735,000
Acquired in-process research and development		(1,202,556	)		(2,220,000	)
Foreign tax credit		330,000			--
Other		19,241			424,000
Deferred tax asset, excluding valuation allowance		36,270,923			29,408,000

Less valuation allowance		(36,270,923	)		(29,408,000	)
Net deferred tax assets	$	--		$	--

The Company recorded $330,000 in income tax expense for the year ended December 31, 2012, as a result of South Korean taxes withheld associated with the Ildong sublicense agreement (see Note 8). There was no current or deferred income tax expense for the year ended December 31, 2011. Income tax expense differed from amounts computed by applying the US federal income tax rate of 34% to pretax loss as follows:

	For the year ended December 31,
	2012			2011

Loss before income taxes, as reported in the consolidated statements of operations	$	(25,852,952	)	$	(889,071	)

Computed “expected” tax benefit	$	(8,790,003	)	$	(302,284	)

Increase (decrease) in income taxes resulting from:
Expected expense (benefit) from state and local taxes		(1,758,001	)		(60,457	)
Research and development credits		(75,000	)		(75,000	)
Other		230,643			(277	)
Foreign tax withholding		330,000			--
Change in the balance of the valuation allowance for deferred tax assets		10,392,361			438,018
	$	330,000		$	--

We file income tax returns in the U.S Federal and various state and local jurisdictions. With certain exceptions, the Company is no longer subject to U.S. Federal and state income tax examinations by tax authorities for years prior to 2009. However, NOLs and tax credits generated from those prior years could still be adjusted upon audit.

The Company recognizes interest and penalties to uncertain tax position in income tax expense in the statement of operations. There was no accrual for interest and penalties related to uncertain tax positions for 2012. We do not believe that there will be a material change in our unrecognized tax positions over the next twelve months. All of the unrecognized tax benefits, if recognized, would be offset by the valuation allowance.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

LICENSE AGREEMENTS

12 Months Ended

Dec. 31, 2012

Licenseagreement [Abstract]

License Agreement Disclosure [Text Block]

NOTE 8 – LICENSE AGREEMENTS

TG-1101

In April 2011, TG Bio acquired from LFB Biotechnologies, a fully owned subsidiary of France based LFB S.A., an option (the “License Option”) for exclusive worldwide rights (except France/Belgium) to develop and market ublituximab (“TG-1101”), a monoclonal antibody that targets a specific epitope on the B-lymphocyte CD20 antigen. In exchange for the License Option, TG Bio issued 132,000 shares of its common stock to LFB.

On January 30, 2012, TG Bio exercised the License Option and entered into an exclusive license agreement with LFB Biotechnologies, GTC Biotherapeutics and LFB/GTC LLC, all wholly-owned subsidiaries of LFB Group, relating to the development of ublituximab (the “License Agreement”). Under the License Agreement, we acquired the exclusive worldwide rights (exclusive of France/Belgium) for the development and commercialization of TG-1101 (ublituximab). To date, we have made no payments to LFB Group, who is eligible to receive payments of up to an aggregate of approximately $31.0 million upon our successful achievement of certain clinical development, regulatory and sales milestones, in addition to royalty payments on net sales of ublituximab. The license will terminate on a country by country basis upon the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated.

In connection with the License Agreement, our subsidiary TG Bio issued 7,368,000 shares of its common stock to LFB Group, and the Company agreed to contribute $15 million, less applicable fees and expenses associated with the financing, to TG Bio to fund the development of ublituximab under the License Agreement in exchange for 7,500,000 shares of TG Bio common stock. The Company recognized approximately $16,578,000 of noncash research and development expense during the year ended December 31, 2012 in connection with the issuance of these shares. In addition, in connection with this share issuance, the Company and TG Bio provided LFB Group the option to, in its sole discretion, elect to convert its shares of TG Bio common stock into 7,500,000 shares of the Company’s Common Stock. Furthermore, should LFB Group choose to exercise the option for Company Common Stock, the Board of Directors of the Company shall appoint an individual designated by LFB Group to serve as a director of the Company until the next annual meeting of the stockholders and until his or her successor has been duly elected. Thereafter the Board of Directors of the Company shall nominate a designee named by LFB Group for election at each annual meeting of the stockholders until such time as LFB Group owns less than 10% of the outstanding Company Common Stock.

On November 9, 2012, LFB Group exercised their right to exchange their TG Bio common stock for Company Common Stock. The Company and LFB Group entered into a Securities Exchange Agreement pursuant to which, LFB Group agreed to exchange its 7,500,000 shares of the common stock of TG Bio, for 5,000,000 shares of Company Common Stock, and a warrant to purchase an aggregate of 2,500,000 shares of Company Common Stock at a purchase price of $0.001 per share. In addition, upon the occurrence of certain financing conditions, the Securities Exchange Agreement requires LFB Group to purchase at least $750,000 in additional shares of Company Common Stock at a purchase price per share equal to the then current Market Price (as defined therein). In addition on November 9, 2012, in connection with the Securities Exchange Agreement, the Board of Directors (the “Board”) of the Company appointed Dr. Yann Echelard to the Board as LFB Group’s nominee. Dr. Echelard will serve as a director until his term expires at the 2013 annual meeting of stockholders, at which time he will stand for reelection by the Company’s stockholders. Effective November 9, 2012, in connection with the aforementioned Securities Exchange Agreement, TG Bio became a wholly owned subsidiary of the Company.

TG-1101 – Ildong Sublicense

In November 2012, we entered into an exclusive (within the territory) sublicense agreement with Ildong Pharmaceutical Co. Ltd, (“Ildong”) relating to the development and commercialization of ublituximab in South Korea and Southeast Asia. Under the terms of the sublicense agreement, Ildong has been granted a royalty bearing, exclusive right, including the right to grant sublicenses, to develop and commercialize ublituximab in South Korea, Taiwan, Singapore, Indonesia, Malaysia, Thailand, Philippines, Vietnam, and Myanmar.

An upfront payment of $2,000,000, which was received in December 2012 net of $330,000 of income tax withheld, is being recognized as license revenue on a straight-line basis over the life of the agreement, which is through the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated, and represents the estimated period over which the Company will have certain ongoing responsibilities under the sublicense agreement. The Company recorded license revenue of approximately $19,000 and $0 for the years ended December 31, 2012 and 2011, respectively, and, at December 31, 2012 and 2011, has deferred revenue of approximately $1,981,000 and $0, respectively, associated with this $2,000,000 payment (approximately $152,000 of which has been classified as a current liability at December 31, 2012).

The Company may receive up to an additional $5.0 million in payments upon the achievement of pre-specified milestones. In addition, upon commercialization, Ildong will make royalty payments to the Company on net sales of TG-1101 in the sublicense territory.

TGR-1202

On August 15, 2012, the Company and Rhizen Pharmaceuticals S A (“Rhizen”) entered into an exclusive global agreement to collaborate on the development and commercialization of Rhizen’s lead product candidate (the “Collaboration Agreement”), a novel P13K delta inhibitor, (“TGR-1202”) (previously referred to as RP5264). The companies will jointly develop the product on a worldwide basis, excluding India, initially focusing on indications in the area of hematologic malignancies and autoimmune disease. Beyond TGR-1202, Rhizen would contribute backup molecules providing multiple opportunities for TG to develop differentiated therapies against hematologic cancers and autoimmune diseases.

The Company will make up-front licensing payments and milestones based on early clinical development, and will be responsible for the costs of clinical development of the product through Phase II, after which the Company and Rhizen will be jointly responsible for all development costs of the product. The Company and Rhizen will each maintain an exclusive option, exercisable at specific times during development, for the Company to license the rights to TGR-1202, in which case Rhizen would be eligible to receive upfront, development, and commercialization milestone payments in addition to milestone payments and royalties tied to net sales of the product, the aggregate of which could exceed $250 million. Rhizen shall maintain rights to manufacture and supply the product to the Company, and the Company will be responsible for all clinical and regulatory development for TGR-1202 globally.

In connection with the Collaboration Agreement, the Company incurred upfront milestone payments of $1,000,000 during the year ended December 31, 2012, which has been included in other research and development expenses in the accompanying consolidated financial statements. Rhizen is eligible to receive additional payments of up to $2,000,000 upon the successful achievement of certain clinical development milestones prior to entering profit and loss sharing for the TGR-1202 development program. Pursuant to the terms of the Collaboration Agreement, should either of the exclusive license options be exercised, Rhizen would be eligible to receive up to an aggregate of $182.5 million upon the successful achievement of certain clinical development, regulatory, and sales based milestones in addition to royalties on net sales of TGR-1202.

JOINT VENTURE

12 Months Ended

Dec. 31, 2012

Equity Method Investments and Joint Ventures [Abstract]

Equity Method Investments and Joint Ventures Disclosure [Text Block]

NOTE 9 – JOINT VENTURE

On April 19, 2011, H Pharmaceuticals K/S (the “Hedrin JV”), of which the Company was a 15% limited partner at the time, filed a demand for arbitration against Thornton & Ross, LTD. (“T&R”) with respect to alleged breaches by T&R of an Exclusive License Agreement (the “Hedrin License”) dated June 28, 2007, which was originally entered into between the Company and T&R, and which the Company assigned in 2008 to the Hedrin JV, with T&R’s consent. The Hedrin JV is seeking damages from T&R in the amount of approximately $7,000,000. The Company was not a party to the initial arbitration demand.

On May 20, 2011, T&R filed an answer to the arbitration demand in which T&R asserted counterclaims against the Hedrin JV for alleged breaches by the Hedrin JV of the Hedrin License and for declaratory relief that the Hedrin License was properly terminated by T&R. In addition, T&R impleaded an individual (who is not associated with the Company), Nordic Biotech Venture Fund II K/S (an investment fund) and the Company, demanding arbitration against them based on alleged breaches of the Hedrin License and other related claims. In December 2011, the Company was removed by the arbitrator as a party to the arbitration. T&R is seeking damages of approximately $20,000,000.

The Hedrin JV and T&R held a mediation session in order to avoid the arbitration process. The mediation process did not produce a result. During 2011 Nordic made an additional capital contribution to the Hedrin JV in order to fund the arbitration. As a result of that capital contribution, as of December 31, 2011, the Company owned 13% interest in the Hedrin JV, and no further information has been available since that date. The arbitration process is ongoing.

- Definition

The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.

+ References + Details

RELATED PARTY TRANSACTIONS

12 Months Ended

Dec. 31, 2012

NOTE 10 – RELATED PARTY TRANSACTIONS

On December 30, 2011, OPN Capital Markets (“OPNCM”) and its affiliated broker-dealer, National Securities Corporation (“NSC” and collectively with OPNCM, “National”), both affiliates of National Holdings Corporation (“National Holdings”), entered into a Placement Agency Agreement (the “PAA”) with the Company in connection with the initial closing of the 2011 Equity PIPE. Pursuant to the PAA, National acted as the Company’s placement agent for 2011 Equity PIPE.

Until April 2012, Michael S. Weiss was a director and Non-Executive Chairman of the Board of Directors of National Holdings. He is also a stockholder of National Holdings and, when combined with his ownership indirectly through Opus and its affiliates, beneficially owns approximately 6.7% of National Holdings, the parent company of NSC. Mr. Weiss disclaims such beneficial ownership other than to the extent of his pecuniary interest. In addition, at the time, Opus and NSC were parties to a 50/50 joint venture that shared profits from OPNCM, the investment banking division of NSC that was responsible for managing the Offering. This joint venture was dissolved in April 2012.

As placement agent, National received cash commissions equal to 10% of the gross proceeds of the 2011 Equity PIPE, five-year warrants to purchase shares of Company Preferred Stock equal to 10% of shares sold in the 2011 Equity PIPE, and a non-accountable expense allowance equal to two percent of the gross proceeds of the 2011 Equity PIPE for National’s expenses (not including up to $80,000 of National’s legal expenses and any blue sky fees, both of which the Company also reimbursed). In connection with the dissolution of the joint venture, in January 2013 National waived all rights to and surrendered to Opus the warrants discussed above. In addition to acting as placement agent, National provided advisory services in connection with the Exchange Transaction and received an advisory fee of $150,000 for such services.

Under the terms of the Company’s License Agreement with LFB Group, the Company utilizes LFB Group for certain development and manufacturing services. The Company incurred approximately $1,447,000 and $0 in such expenses during the years ended December 31, 2012 and 2011, respectively, which have been included in other research and development expenses in the accompanying consolidated statements of operations. As of December 31, 2012, the Company has approximately $56,000 recorded in accounts payable related to the aforementioned agreements with LFB Group. In conjunction with the development and manufacturing services discussed above, certain agreements between the Company and LFB Group require payments in advance of services performed or goods delivered. Accordingly, as of December 31, 2012, the Company recorded $1,719,828 in prepaid research and development for such advance payments.

In connection with the Collaboration Agreement with Rhizen in August 2012, the Company issued Opus 2,000,000 shares of Company common stock subject to certain vesting provisions based on the progress of the joint venture and future success of the products governed by the Collaboration Agreement. The issuance of the Company Common Stock was exempt from registration under the Securities Act of 1933 pursuant to Regulation D and Rule 506 promulgated thereunder. Accordingly, the securities have not been registered under the Securities Act, and until so registered, these securities may not be offered or sold in the United States absent registration or availability of an applicable exemption from registration. The Company recognized approximately $134,000 of noncash compensation (research and development) expense during the year ended December 31, 2012 in connection with the issuance of these shares.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph b
-Article 3A

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph k
-Article 4

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 57
-Paragraph 1-4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2012

Accounting Policies [Abstract]

Business Description [Policy Text Block]

DESCRIPTION OF BUSINESS

Exchange Transaction with TG Therapeutics, Inc. and its majority shareholders

The filings with the Securities and Exchange Commission (the “SEC”) include the historical financial results of TG Bio and will hereafter collectively be referred to as the Company.

Correction Of Immaterial Error [Policy Text Block]

CORRECTION OF AN IMMATERIAL ERROR

In-process research and development decreased from $5,441,839 to $3,902,300

Goodwill increased from $629,752 to $799,391

Notes payable, less current portion, at fair value decreased from $4,664,697 to $3,294,797

The net effect of this adjustment is a decrease to total assets and liabilities, as previously reported, of $1,369,900.

Liquidity Disclosure [Policy Text Block]

LIQUIDITY AND CAPITAL RESOURCES

Our common stock is quoted on the OTC Bulletin Boardand trades under the symbol “TGTX.”

Reverse Stock Split [Policy Text Block]

REVERSE STOCK SPLIT

2011 Management Changes [Policy Text Block]

2011 MANAGEMENT CHANGES

New Accounting Pronouncements, Policy [Policy Text Block]

RECENTLY ISSUED ACCOUNTING STANDARDS

Basis of Accounting, Policy [Policy Text Block]

BASIS OF PRESENTATION

Use of Estimates, Policy [Policy Text Block]

USE OF ESTIMATES

Cash and Cash Equivalents, Policy [Policy Text Block]

CASH AND CASH EQUIVALENTS

We treat liquid investments with original maturities of less than three months when purchased as cash and cash equivalents.

Revenue Recognition, Policy [Policy Text Block]

REVENUE RECOGNITION

Research and Development Expense, Policy [Policy Text Block]

RESEARCH AND DEVELOPMENT COSTS

In Process Research and Development, Policy [Policy Text Block]

IN-PROCESS RESEARCH AND DEVELOPMENT

Income Tax, Policy [Policy Text Block]

INCOME TAXES

We recognize interest and penalties related to uncertain income tax positions in income tax expense.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

STOCK - BASED COMPENSATION

Earnings Per Share, Policy [Policy Text Block]

BASIC AND DILUTED NET (LOSS) INCOME PER COMMON SHARE

Impairment Of Tangible and Intangible Asset Including Goodwill [Policy Text Block]

LONG LIVED ASSETS AND GOODWILL

CASH AND CASH EQUIVALENTS (Tables)

12 Months Ended

Dec. 31, 2012

Cash and Cash Equivalents [Abstract]

Schedule of Cash and Cash Equivalents [Table Text Block]

	December 31, 2012		December 31, 2011

Checking and bank deposits	$	16,455,995	$	9,748,491
Total	$	16,455,995	$	9,748,491

FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Dec. 31, 2012

Fair Value Disclosures [Abstract]

Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]

The Company’s financial liabilities measured at fair value on a recurring basis as of December 31, 2012 and 2011 were as follows:

	Financial liabilities at fair value as of December 31, 2012
	Level 1		Level 2		Level 3		Total

5% Notes	$	--	$	--	$	2,479,098	$	2,479,098
Totals	$	--	$	--	$	2,479,098	$	2,479,098

	Financial liabilities at fair value as of December 31, 2011
	Level 1		Level 2		Level 3		Total

5% Notes	$	--	$	--	$	3,294,797	$	3,294,797
Totals	$	--	$	--	$	3,294,797	$	3,294,797

Change In Level Three Fair Value During Period [Table Text Block]

The following table summarizes the changes in Level 3 instruments for the years ended December 31, 2011 and 2012:

Balance at January 1, 2011	$	--
Transfer into Level 3		3,287,700
Interest accrued on face value of 5% Notes		7,097
Change in fair value of Level 3 liabilities		--
Balance at December 31, 2011		3,294,797
Interest accrued on face value of 5% Notes		844,173
Change in fair value of Level 3 liabilities		(1,659,872)
Balance at December 31, 2012	$	2,479,098

Fair Value Measurements, Nonrecurring [Table Text Block]

The Company’s assets measured at fair value on a nonrecurring basis as of December 31, 2012 were as follows:

	Fair value measurements as of December 31, 2012
	Level 1		Level 2		Level 3		Total impairment charge for the year ended December 31, 2012
Assets:
In-process research and development	$	--	$	--	$	2,797,600	$	(1,104,700	)
Total	$	--	$	--	$	2,797,600	$	(1,104,700	)

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring and/or nonrecurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References + Details

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References + Details

ACQUISITION (Tables)

12 Months Ended

Dec. 31, 2012

Business Combinations [Abstract]

Schedule Of Purchase Price Consideration [Table Text Block]

A summary of the purchase price calculation is as follows:

Number of shares of Manhattan common stock outstanding at the time of the transaction		131,526
Multiplied by Manhattan’s fair value of the Common Stock	$	2.25	$	295,933
Fair value of restricted stock assumed				82,305
Total purchase price			$	378,238

Schedule of Purchase Price Allocation [Table Text Block]

The purchase price has been allocated as follows based on the fair values of the assets and liabilities acquired:

Cash and cash equivalents	$	10,386
Other assets		90,770
In-process research and development acquired		3,902,300
Total identifiable assets		4,003,456
Accounts payable and accrued expenses		197,191
Notes payable (ICON and Swiss Pharma)		939,718
5% notes payable and accrued interest		3,287,700
Total identifiable liabilities		4,424,609
Net identifiable assets (liabilities)		(421,153	)
Goodwill		799,391
Total	$	378,238

Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table Text Block]

The following supplemental pro forma information presents the financial results as if the transaction had occurred on January 1, 2011 for the year ended December 31, 2011. This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2011, nor are they indicative of future results.

	2011
Revenue	$	--
Net loss	$	(818,279	)
Basic and diluted loss per common share	$	(0.31	)

- Definition

Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.

+ References + Details

STOCKHOLDERS' EQUITY (Tables)

12 Months Ended

Dec. 31, 2012

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes stock option activity for the years ended December 31, 2012 and 2011:

	Number of shares			Weighted- average exercise price		Weighted- average Contractual Term		Aggregate Intrinsic Value
						(in years)
Outstanding at January 1, 2011		--			--
Assumed in Exchange Transaction		4,143		$	1,375.18		5.60
Granted		--			--
Exercised		--			--
Forfeited		(364	)		197.34
Expired		(400	)		2,951.12
Outstanding at December 31, 2011		3,379			1,315.62		6.39	$	--
Granted		46,000			4.40
Exercised		--			--
Forfeited		(2,475	)		720.45
Expired		--			--
Outstanding at December 31, 2012		46,904		$	61.08		9.44	$	--

Vested and expected to vest at December 31, 2012		904		$	2,945.09		1.73	$	--
Exercisable at December 31, 2012		898		$	2,963.46		1.70	$	--

Schedule Of Warrants Activity [Table Text Block]

The following table summarizes warrant activity for the years ended December 31, 2012 and 2011:

	Warrants			Weighted- average exercise price		Aggregate Intrinsic Value
Outstanding at January 1, 2011		--		$	--
Assumed in Exchange Transaction		393,437			14.74
Issued		1,232,474			2.25
Exercised		--			--
Expired		--			--
Outstanding at December 31, 2011		1,625,911			5.27	$	--
Issued		5,156,599			1.21
Exercised		--			--
Expired		(1,503	)		2,739.75
Outstanding at December 31, 2012		6,781,007		$	1.58	$	14,563,539

Schedule Of Share Based Compensation Expense [Table Text Block]

The following table summarizes stock-based compensation expense information about stock options and restricted stock for the years ended December 31, 2012 and 2011:

	2012		2011

Stock-based compensation expense associated with restricted stock	$	3,422,182	$	86,494
Stock-based compensation expense associated with option grants		--		--
	$	3,422,182	$	86,494

Preferred Restricted Stock [Member]

Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]

	Number of Shares Restricted Series A Preferred Stock⁽¹⁾			Weighted Average Grant Date Fair Value
Outstanding at January 1, 2011		--		$	--
Granted		129,375			20.00
Vested		--			--
Forfeited		--			--
Outstanding at December 31, 2011		129,375			20.00
Granted		--			--
Vested		--			--
Forfeited		--			--
Conversion to restricted common stock		(129,375	)		20.00
Outstanding at December 31, 2012		--		$	--

Common Restricted Stock [Member]

Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]

	Number of Shares			Weighted Average Grant Date Fair Value
Outstanding at January 1, 2011		--		$	--
Granted		--			--
Vested		--			--
Forfeited		--			--
Outstanding at December 31, 2011		--			--
Converted preferred stock		1,150,000			2.25
Granted		5,901,743			4.77
Vested		(437,500	)		2.25
Forfeited		--		--
Outstanding at December 31, 2012		6,614,243		$	4.49

NOTES PAYABLE (Tables)

12 Months Ended

Dec. 31, 2012

Debt Disclosure [Abstract]

Schedule of Debt [Table Text Block]

The following is a summary of notes payable:

	December 31, 2012						December 31, 2011
	Current portion, net		Non- current portion, net		Total		Current portion, net		Non- current portion, net		Total
Non-interest Bearing Note Payable, Net	$	--	$	-	$	--	$	200,000	$	-	$	200,000
Convertible 5% Notes Payable		-		2,479,098		2,479,098		-		3,294,797		3,294,797
ICON Convertible Note		677,778		-		677,778		677,778		-		677,778
Total	$	677,778	$	2,479,098	$	3,156,876	$	877,778	$	3,294,797	$	4,172,575

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2012

Income Tax Disclosure [Abstract]

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2012 and 2011 are presented below.

	2012			2011
Deferred tax assets (liabilities):
Net operating loss carryforwards	$	32,190,080		$	27,611,000
Research and development credit		1,882,238			1,858,000
Non-cash compensation		3,051,920			1,735,000
Acquired in-process research and development		(1,202,556	)		(2,220,000	)
Foreign tax credit		330,000			--
Other		19,241			424,000
Deferred tax asset, excluding valuation allowance		36,270,923			29,408,000

Less valuation allowance		(36,270,923	)		(29,408,000	)
Net deferred tax assets	$	--		$	--

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

Income tax expense differed from amounts computed by applying the US federal income tax rate of 34% to pretax loss as follows:

	For the year ended December 31,
	2012			2011

Loss before income taxes, as reported in the consolidated statements of operations	$	(25,852,952	)	$	(889,071	)

Computed “expected” tax benefit	$	(8,790,003	)	$	(302,284	)

Increase (decrease) in income taxes resulting from:
Expected expense (benefit) from state and local taxes		(1,758,001	)		(60,457	)
Research and development credits		(75,000	)		(75,000	)
Other		230,643			(277	)
Foreign tax withholding		330,000			--
Change in the balance of the valuation allowance for deferred tax assets		10,392,361			438,018
	$	330,000		$	--

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($)

1 Months Ended

12 Months Ended

Dec. 29, 2011

Dec. 31, 2012

Dec. 31, 2011

Nov. 30, 2011

Dec. 31, 2010

Dec. 31, 2009

Business Acquisition, Equity Interest Issued Or Issuable, Number Of Shares

281,250

Convertible Preferred Stock, Shares Issued upon Conversion

8.89

Deficit accumulated in development stage

$ 18,925,793

$ 853,074

Cash and Cash Equivalents, At Carrying Value

$ 16,455,995

$ 9,748,491

$ 0

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount

10,746,837

5,320,173

Business acquisition shares not surrendered

132,000

Business Acquisition Shares Repurchased Percentage

95.00%

In-process research and development

$ 2,797,600

$ 3,902,300

Goodwill

799,391

Notes payable, noncurrent portion, at fair value

$ 2,479,098

3,294,797

Period Anticipated Sufficient To Fund Operating Cash Flow

18 months

Stockholders' Equity, Reverse Stock Split

Ratio of 56.25 for 1

Decrease To Total Assets And Liabilities

1,369,900

Cash Equivalents Maturity Period

less than three months

Before Correction Of Immaterial Error [Member]

In-process research and development

5,441,839

Goodwill

629,752

Notes payable, noncurrent portion, at fair value

4,664,697

After Correction Of Immaterial Error [Member]

In-process research and development

3,902,300

Goodwill

799,391

Notes payable, noncurrent portion, at fair value

$ 3,294,797

Series Preferred Stock [Member]

Convertible Preferred Stock, Shares Issued upon Conversion

8.89

Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period

^[1]

129,375

Series Preferred Stock [Member] | Mr.Power [Member]

Convertible Preferred Stock, Shares Issued upon Conversion

8.89

Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period

16,875

Series Preferred Stock [Member] | Mr.Weiss [Member]

Convertible Preferred Stock, Shares Issued upon Conversion

8.89

Percentage Of Outstanding Shares Granted Annually

1.25%

Percentage Of Annual Grants Restricted Stock Becoming Non Forfeitable On First Aniversary

25.00%

Percentage Of Annual Grants Restricted Stock That Will Vest And Become Nonforfeitable On Second Aniversary

25.00%

Market Capitalization Increase To Trigger Restricted Stock That Will Vest And Become Nonforfeitable

$ 100,000,000

Percentage Of Restricted Stock That Will Vest And Become Nonforfeitable Upon Market Capitalization Increase

50.00%

Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period

112,500

Tg Bio [Member]

Percentage Of Stock Issued After Exchange Transaction

95.00%

[1]

(1) The restricted preferred stock listed in the table above was granted in connection with the Exchange Transaction to certain executives as discussed above. Each share of preferred stock was convertible into 8.89 shares of the Company's Common Stock. In conjunction with the reverse split effected on April 30, 2012 (as discussed in Note 1), all outstanding restricted Preferred Stock automatically converted to 1,150,000 shares of restricted Common Stock as of that date.

CASH AND CASH EQUIVALENTS (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Nov. 30, 2011	Dec. 31, 2010	Dec. 31, 2009
Checking and bank deposits	$ 16,455,995	$ 9,748,491
Total	$ 16,455,995	$ 9,748,491	$ 0	$ 0	$ 0

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7
-Footnote 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 8, 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

FAIR VALUE MEASUREMENTS (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
5% Notes	$ 2,479,098	$ 3,294,797
Totals	2,479,098	3,294,797
Fair Value, Inputs, Level 1 [Member]
5% Notes	0	0
Totals	0	0
Fair Value, Inputs, Level 2 [Member]
5% Notes	0	0
Totals	0	0
Fair Value, Inputs, Level 3 [Member]
5% Notes	2,479,098	3,294,797
Totals	$ 2,479,098	$ 3,294,797

FAIR VALUE MEASUREMENTS (Details 1) - USD ($)	12 Months Ended
FAIR VALUE MEASUREMENTS (Details 1) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
Balance at January	$ 3,294,797	$ 0
Transfer into Level 3		3,287,700
Interest accrued on face value of 5% Notes	844,173	7,097
Change in fair value of Level 3 liabilities	(1,659,872)	0
Balance at December	$ 2,479,098	$ 3,294,797

FAIR VALUE MEASUREMENTS (Details 2) - USD ($)	12 Months Ended		13 Months Ended
FAIR VALUE MEASUREMENTS (Details 2) - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
In-process research and development	$ 2,797,600	$ 3,902,300	$ 2,797,600
Impairment of in-process research and development	(1,104,700)	$ 0	(1,104,700)
Impairment Charge [Member]
In-process research and development	(1,104,700)		(1,104,700)
Impairment of in-process research and development	(1,104,700)		(1,104,700)
Fair Value, Inputs, Level 1 [Member] \| Nonrecurring [Member]
In-process research and development	0		0
Assets, Fair Value Disclosure, Nonrecurring	0		0
Fair Value, Inputs, Level 2 [Member] \| Nonrecurring [Member]
In-process research and development	0		0
Assets, Fair Value Disclosure, Nonrecurring	0		0
Fair Value, Inputs, Level 3 [Member] \| Nonrecurring [Member]
In-process research and development	2,797,600		2,797,600
Assets, Fair Value Disclosure, Nonrecurring	$ 2,797,600		$ 2,797,600

FAIR VALUE MEASUREMENTS (Details Textual) - USD ($)	12 Months Ended			13 Months Ended
FAIR VALUE MEASUREMENTS (Details Textual) - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2012	Dec. 29, 2011
Impairment of in-process research and development	$ 1,104,700	$ 0		$ 1,104,700
Long-term Debt, Gross	17,727,000	$ 16,883,000		17,727,000	$ 16,876,000
Debt Instrument, Fair Value Disclosure	$ 3,287,700			$ 3,287,700
Fair Value Inputs, Discount Rate	20.00%	20.00%
Repayments Of Long-Term Debt	$ 0
Manhattan and Ariston Pharmaceuticals Merger [Member]
Notes Issued			$ 15,452,793
Debt Instrument Maturity Period			5 years
Debt Instrument, Interest Rate, Effective Percentage	5.00%	5.00%	5.00%	5.00%
Debt Instrument, Convertible, Conversion Price			$ 1,125
Percentage Of Cash Proceeds From Operation To Repay Convertible Debt			50.00%

ACQUISITION (Details)	1 Months Ended
ACQUISITION (Details)	Dec. 29, 2011 USD ($) $ / shares shares
Number of shares of Manhattan common stock outstanding at the time of the transaction \| shares	131,526
Multiplied by Manhattans fair value of the Common Stock (in dollars per share) \| $ / shares	$ 2.25
Multiplied by Manhattans fair value of the Common Stock	$ 295,933
Fair value of restricted stock assumed	82,305
Total purchase price	$ 378,238

ACQUISITION (Details 1)	Dec. 29, 2011 USD ($)
Cash and cash equivalents	$ 10,386
Other assets	90,770
In-process research and development acquired	3,902,300
Total identifiable assets	4,003,456
Accounts payable and accrued expenses	197,191
Total identifiable liabilities	4,424,609
Net identifiable assets (liabilities)	(421,153)
Goodwill	799,391
Total	378,238
Icon and Swiss Pharma [Member]
Notes payable	939,718
Excluding Icon and Swiss Pharma [Member]
Notes payable	$ 3,287,700

ACQUISITION (Details 2)	12 Months Ended
ACQUISITION (Details 2)	Dec. 31, 2011 USD ($) $ / shares
Revenue	$ 0
Net loss	$ (818,279)
Basic and diluted loss per common share (in dollars per shares) \| $ / shares	$ (0.31)

ACQUISITION (Details Textual) - USD ($)	1 Months Ended
ACQUISITION (Details Textual) - USD ($)	Dec. 29, 2011	Dec. 31, 2012
Business Acquisition Shares Repurchased Percentage	95.00%
Business acquisition shares not surrendered	132,000
Convertible Preferred Stock, Shares Issued upon Conversion	8.89
Business Acquisition, Equity Interest Issued Or Issuable, Number Of Shares	281,250
Fair Value Of Shares	$ 2.25
Business Acquisition, Cost of Acquired Entity, Transaction Costs	$ 231,580
Shareholders Description Note Participated In Exchange Transaction	one (1) minority shareholder of TG Bio holding in aggregate 132,000 shares of common stock of TG Bio did not participate
Multiplied by Manhattans fair value of the Common Stock	$ 295,933
Fair value of restricted stock assumed	$ 82,305
Series Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion	8.89	8.89

STOCKHOLDERS' EQUITY (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Number of shares, Outstanding	3,379	0
Number of shares, Assumed in Exchange Transaction		4,143
Number of shares, Granted	46,000	0
Number of shares, Exercised	0	0
Number of shares, Forfeited	(2,475)	(364)
Number of shares, Expired	0	(400)
Number of shares, Outstanding	46,904	3,379
Number of shares, Vested and expected to vest	904
Number of shares, Exercisable	898
weighted-average exercise price, Outstanding	$ 1,315.62	$ 0
weighted-average exercise price, Assumed in Exchange Transaction		1,375.18
weighted-average exercise price, Granted	4.4	0
weighted-average exercise price, Exercised	0	0
weighted-average exercise price, Forfeited	720.45	197.34
weighted-average exercise price, Expired	0	2,951.12
weighted-average exercise price, Outstanding	61.08	$ 1,315.62
weighted-average exercise price, Vested and expected to vest	2,945.09
weighted-average exercise price, Exercisable	$ 2,963.46
Weighted-average contractual Term, Assumed in Exchange Transaction		5 years 7 months 6 days
Weighted-average contractual Term, Outstanding (Beginning balance)	6 years 4 months 21 days
Weighted-average contractual Term, Outstanding (Ending balance)	9 years 5 months 9 days	6 years 4 months 21 days
Weighted-average contractual Term, Vested and expected to vest	1 year 8 months 23 days
Weighted-average contractual Term, Exercisable	1 year 8 months 12 days
Aggregate Intrinsic Value, Outstanding	$ 0	$ 0
Aggregate Intrinsic Value, Vested and expected to vest	0
Aggregate Intrinsic Value, Exercisable	$ 0

STOCKHOLDERS' EQUITY (Details 1) - $ / shares

12 Months Ended

Dec. 31, 2012

Dec. 31, 2011

Restricted Series A Preferred [Member]

Number of Shares, Outstanding

^[1]

129,375

Conversion to restricted stock

^[1]

(129,375)

Number of Shares, Granted

^[1]

129,375

Number of Shares, Vested

^[1]

Number of Shares, Forfeited

^[1]

Number of Shares, Outstanding

^[1]

129,375

Weighted Average Grant Date Fair Value,Outstanding

$ 20

$ 0

Weighted Average Grant Date Fair Value, Granted

Weighted Average Grant Date Fair Value, Vested

Weighted Average Grant Date Fair Value, Forfeited

Conversion to restricted common stock - weighted average grant date fair value

Weighted Average Grant Date Fair Value,Outstanding

$ 0

$ 20

Restricted Common Stock [Member]

Number of Shares, Outstanding

Conversion to restricted stock

1,150,000

Number of Shares, Granted

5,901,743

Number of Shares, Vested

(437,500)

Number of Shares, Forfeited

Number of Shares, Outstanding

6,614,243

Weighted Average Grant Date Fair Value,Outstanding

$ 0

Weighted Average Grant Date Fair Value, Granted

4.77

Weighted Average Grant Date Fair Value, Vested

2.25

Weighted Average Grant Date Fair Value, Forfeited

Conversion to restricted common stock - weighted average grant date fair value

2.25

Weighted Average Grant Date Fair Value,Outstanding

$ 4.49

$ 0

[1]

STOCKHOLDERS' EQUITY (Details 2) - USD ($)	12 Months Ended
STOCKHOLDERS' EQUITY (Details 2) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
Number of Shares, Outstanding	1,625,911	0
Warrants Assumed in Exchange Transaction		393,437
Warrants Issued	5,156,599	1,232,474
Warrants Exercised	0	0
Warrants Expired	(1,503)	0
Number of Shares, Outstanding	6,781,007	1,625,911
Weighted - average exercise price of Warrants Outstanding	$ 5.27	$ 0
Weighted - average exercise price of Warrants Assumed in Exchange Transaction		14.74
Weighted - average exercise price of Warrants Issued	1.21	2.25
Weighted - average exercise price of Warrants Exercised	0	0
Weighted - average exercise price of Warrants Expired	2,739.75	0
Weighted - average exercise price of Warrants Outstanding	$ 1.58	$ 5.27
Aggregate Intrinsic Value of Warrants Outstanding	$ 14,563,539	$ 0

STOCKHOLDERS' EQUITY (Details 3) - USD ($)	12 Months Ended		13 Months Ended
STOCKHOLDERS' EQUITY (Details 3) - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
Stock-based compensation expense associated with restricted stock	$ 3,422,182	$ 86,494
Stock-based compensation expense associated with option grants	0	0
Stock compensation expense	$ 3,422,182	$ 86,494	$ 3,508,676

STOCKHOLDERS' EQUITY (Details Textual)		1 Months Ended			12 Months Ended		13 Months Ended
STOCKHOLDERS' EQUITY (Details Textual)	Nov. 09, 2012 $ / shares shares	Apr. 30, 2012 $ / shares shares	Feb. 24, 2012 USD ($) $ / shares shares	Dec. 30, 2011 USD ($) $ / shares shares	Dec. 31, 2012 USD ($) $ / shares shares	Dec. 31, 2011 USD ($) $ / shares shares	Dec. 31, 2012 USD ($) $ / shares shares	May 17, 2012 USD ($) shares	Dec. 29, 2011 $ / shares shares	Apr. 19, 2011	Dec. 31, 2010 shares
Preferred Stock, Shares Authorized					10,000,000	10,000,000	10,000,000
Common Stock, Shares Authorized					500,000,000	500,000,000	500,000,000
Preferred Stock, Par Or Stated Value Per Share \| $ / shares					$ 0.001	$ 0.001	$ 0.001
Preferred Stock, Shares Outstanding					0	413,388	0
Convertible Preferred Stock Share Converted Into Common Stock					1,150,000		1,150,000		500
Common stock, par value (in dollars per share) \| $ / shares					$ 0.001	$ 0.001	$ 0.001
Stock Issued During Period, Shares, New Issues			695,428
Fair Value Per Share Issued \| $ / shares				$ 2.25
Proceeds from Issuance of Private Placement \| $			$ 13,908,560	$ 11,091,425
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,545,396		1,232,381	2,777,962		2,777,962
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares		2.25		2.25	2.25		2.25
Class Of Warrant Or Rights Exercisable Period		5 years		5 years
Agent Cash Commission Percentage On Proceeds From Shares Issuance				10.00%
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Yet To Be Recognized					less than $1,000
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition					3 months
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized \| $					$ 8,941,000		$ 8,941,000
Stock compensation expense \| $					$ 3,422,182	$ 86,494	$ 3,508,676
Preferred Stock To Common Stock Conversion Basis Per Share						8.89
Share Based Compensation Non Employee Stock Options Outstanding					46,000		46,000
Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Outstanding Number					46,904	3,379	46,904				0
Treasury stock					13,526	0	13,526
Number of shares, Vested and expected to vest					904		904
Treasury Stock, Value \| $					$ 84,538	$ 0	$ 84,538
Equity Method Investments \| $					$ 8,479,000		$ 8,479,000
Equity Method Investment, Ownership Percentage					13.00%		13.00%			15.00%
Common Stock Pivate Placement				4,929,523
Preferred Stock, Liquidation Preference Per Share \| $ / shares			$ 20						$ 20
Non Employee Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Outstanding Number					2,580,000		2,580,000
Corporate Mile Stone [Member]
Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Outstanding Number					2,092,500		2,092,500
Private Placement [Member] \| Two Thousand Twelve Issuance [Member]
Agent Cash Commission Percentage On Proceeds From Shares Issuance				10.00%
Placement Agent [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					1,111,111		1,111,111
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares					2.48		2.48
Lfb [Member]
Conversion Of Stock, Shares Converted	7,500,000
Conversion of Stock, Shares Issued	5,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	0.001
Tg Bio [Member]
Equity Method Investment, Ownership Percentage					42.90%		42.90%
Restricted Stock [Member]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition					2 years 9 months 18 days
Treasury stock					13,526		13,526	13,526
Number of shares, Vested and expected to vest								37,500
Treasury Stock, Value \| $								$ 85,000
2012 Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award Options Reserved For Future Issuance					6,000,000		6,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant					2,052,257		2,052,257
Share Based Compensation Non Employee Stock Options Outstanding					46,000		46,000
Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Outstanding Number					46,000		46,000
Equity Pipe 2011 [Member]
Warrants Exercised Either By Placement Agent Or Warrants Issued					0
Series Preferred Stock [Member] \| Two Thousand Eleven Issuance [Member]
Warrant Term					5 years
Agent Warrant Percentage On Issuance Of Shares					10.00%
Agent Non Accountable Expense Percentage On Gross Proceeds From Share Issuance					2.00%
2012 Stock Option Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award Options Reserved For Future Issuance					5,333		5,333
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant					4,732		4,732
Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Outstanding Number					591		591
Share Based Compensation Arrangement By Share Based Payment Award Options Maximum Term					10 years		10 years
Share Based Compensation Arrangement By Share Based Payment Award Options Issued					10		10
1995 Stock Option Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award Options Reserved For Future Issuance					2,600		2,600
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant					0		0
Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Outstanding Number					313		313
Preferred Stock [Member]
Convertible Preferred Stock Share Converted Into Common Stock		9,857,596
Preferred Stock To Common Stock Conversion Basis Per Share		8.89

NOTES PAYABLE (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
Notes payable, current portion	$ 677,778	$ 877,778
Non-current portion, net	2,479,098	3,294,797
Total	3,156,876	4,172,575
Non - Interest Bearing [Member]
Notes payable, current portion	0	200,000
Non-current portion, net	0	0
Total	0	200,000
Convertible Notes [Member]
Notes payable, current portion	0	0
Non-current portion, net	2,479,098	3,294,797
Total	2,479,098	3,294,797
ICON Convertible Notes [Member]
Notes payable, current portion	677,778	677,778
Non-current portion, net	0	0
Total	$ 677,778	$ 677,778

NOTES PAYABLE (Details Textual) - USD ($)		1 Months Ended	12 Months Ended		13 Months Ended
NOTES PAYABLE (Details Textual) - USD ($)	Mar. 08, 2010	Oct. 31, 2009	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 29, 2011	Nov. 01, 2011	Oct. 27, 2011	Mar. 31, 2011
Ariston [Member]
Debt Instrument, Interest Rate, Stated Percentage			5.00%		5.00%
Debt Instrument, Convertible, Conversion Price				$ 10
Icon Clinical Research [Member]
Debt Instrument, Interest Rate, Stated Percentage	5.00%		5.00%		5.00%
Accounts Payable	$ 1,275,188
Payments of short-term loans	275,188
Debt Instrument, Periodic Payment, Principal	$ 27,778
One Time Settlement Amount For Waiver Of Interest and Principal Payments									$ 100,000
Interest and Debt Expense			$ 61,571
Notes payable, current portion			677,778	$ 677,778	$ 677,778
Interest Payable			$ 123,511	61,941	$ 123,511
Debt Instrument Repayment Term	36 months
Settlement Agreement Payment		$ 200,000
Waiver Period			13 months
Promissory Note Issued								$ 250,000
Debt Instrument Renegotiated Price							$ 200,000
Debt Instrument, Interest Rate, Stated Percentage			5.00%		5.00%
Percentage Of Cash Proceeds From Operation To Repay Interest On Convertible Debt			50.00%
Long-term Debt, Gross			$ 17,727,000	16,883,000	$ 17,727,000	$ 16,876,000
Payments of short-term loans			200,001	0	200,001
Notes payable, current portion			677,778	877,778	677,778
Debt Instrument, Maturity Date		Feb. 15, 2012
Total			3,156,876	$ 4,172,575	3,156,876
Convertible Notes Payable [Member]
Debt Instrument, Convertible, Conversion Price	$ 1,125
Debt Instrument, Maturity Date	Mar. 08, 2015
Exchange Transaction [Member]
Total			$ 3,287,700		$ 3,287,700
Before Amendment [Member] \| Icon Clinical Research [Member]
Debt Instrument, Interest Rate, Stated Percentage									5.00%
After Amendment [Member] \| Icon Clinical Research [Member]
Debt Instrument, Interest Rate, Stated Percentage									8.00%
Debt Instrument, Convertible, Conversion Price									$ 562.5

INCOME TAXES (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
Deferred tax assets (liabilities):
Net operating loss carryforwards	$ 32,190,080	$ 27,611,000
Research and development credit	1,882,238	1,858,000
Non-cash compensation	3,051,920	1,735,000
Acquired in-process research and development	(1,202,556)	(2,220,000)
Foreign tax credit	330,000	0
Other	19,241	424,000
Deferred tax asset, excluding valuation allowance	36,270,923	29,408,000
Less valuation allowance	(36,270,923)	(29,408,000)
Net deferred tax assets	$ 0	$ 0

INCOME TAXES (Details 1) - USD ($)	12 Months Ended		13 Months Ended
INCOME TAXES (Details 1) - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
Loss before income taxes, as reported in the consolidated statements of operations	$ (25,852,952)	$ (889,071)	$ (26,742,023)
Computed "expected" tax benefit	(8,790,003)	(302,284)
Increase (decrease) in income taxes resulting from:
Expected expense (benefit) from state and local taxes	(1,758,001)	(60,457)
Research and development credits	(75,000)	(75,000)
Other	230,643	(277)
Foreign tax withholding	330,000	0
Change in the balance of the valuation allowance for deferred tax assets	10,392,361	438,018
Income Tax Expense (Benefit)	$ 330,000	$ 0	$ 330,000

- Definition

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to pretax Income or Loss from continuing operations; income tax expense or benefit may include interest and penalties on tax uncertainties based on the entity's accounting policy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32247-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32672-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 45, 46
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 48
-Paragraph 15, 16, 19
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

INCOME TAXES (Details Textual) - USD ($)	12 Months Ended		13 Months Ended
INCOME TAXES (Details Textual) - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
Deferred Tax Assets, Valuation Allowance	$ 36,270,923	$ 29,408,000	$ 36,270,923
Income Tax Expense (Benefit)	330,000	$ 0	330,000
Us Federal Income Tax [Member]
Operating Loss Carryforwards	$ 83,637,000		$ 83,637,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	34.00%	34.00%
Operating Loss Carryforwards, Expiration Dates	2032

LICENSE AGREEMENTS (Details Textual)		12 Months Ended		13 Months Ended
LICENSE AGREEMENTS (Details Textual)	Nov. 09, 2012 USD ($) $ / shares shares	Dec. 31, 2012 USD ($) $ / shares shares	Dec. 31, 2011 USD ($) shares	Dec. 31, 2012 USD ($) $ / shares shares	Apr. 30, 2012 $ / shares shares	Dec. 30, 2011 $ / shares shares
Noncash stock expense associated with in-licensing agreement		$ 16,578,000	$ 297,000	$ 16,875,000
Potential future milestone payments		250,000,000
Upfront Fee Received From Sub License		2,000,000
Licenses Revenue		19,048	0	19,048
Deferred Revenue		1,981,000	0	$ 1,981,000
Additional Amount Receivable On Achievement Of Pre Specified Milestones		$ 5,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares		2,777,962		2,777,962	1,545,396	1,232,381
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares		2.25		2.25	2.25	2.25
Income taxes		$ 330,000	0	$ 330,000
Current portion of deferred revenue		152,381	$ 0	$ 152,381
Lfb Biotechnologies [Member]
Stock Issued During Period Shares License Option \| shares			132,000
Business Development		$ 31,000,000
Bussiness Acquisiton Purchase Agreement Period Description		The license will terminate on a country by country basis upon the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated.
Sale of Stock, Number of Shares Issued in Transaction \| shares		7,368,000
Contribution Per Licence Agreement In Exchange Of Common Stock		$ 15,000,000
Common Stock Shares Subscribed Subsidiary Sale Of Stock \| shares		7,500,000
Shares Issued For Licence Agreement Exchange \| shares		7,500,000
Noncontrolling Interest, Description		The Board of Directors of the Company shall nominate a designee names by LFB Group for election at each annual meeting of the stockholders until such time as LFB Group owns less than 10% of the outstanding Company Common Stock.
Converted Shares \| shares	7,500,000
Conversion of Stock, Shares Issued \| shares	5,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares	2,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	0.001
Incremental Common Share Attributable To Security Exchange Agreement	$ 750,000
Collaboration Agreement [Member]
Milestone Payment		$ 1,000,000
Potential future milestone payments		2,000,000
Potential Additional Amount Payable On Achievement Of Pre Specified Milestones		$ 182,500,000

JOINT VENTURE (Details Textual) - USD ($)	12 Months Ended
JOINT VENTURE (Details Textual) - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Apr. 19, 2011
Loss Contingency, Damages Sought, Value	$ 7,000,000
Equity Method Investment, Ownership Percentage	13.00%		15.00%
Thornton Ross, Ltd [Member]
Loss Contingency, Damages Sought, Value		$ 20,000,000

- Definition

The value (monetary amount) of the award the plaintiff seeks in the legal matter.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14557-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 11
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

RELATED PARTY TRANSACTIONS (Details Textual) - USD ($)	1 Months Ended		12 Months Ended		13 Months Ended
RELATED PARTY TRANSACTIONS (Details Textual) - USD ($)	Feb. 24, 2012	Dec. 30, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Apr. 30, 2012	Apr. 19, 2011
Equity Method Investment, Ownership Percentage			13.00%		13.00%		15.00%
Agent Cash Commission Percentage On Proceeds From Shares Issuance		10.00%
Other research and development			$ 3,994,182	$ 30,283	$ 4,024,465
Prepaid research and development			1,990,759		1,990,759
Stock Issued During Period, Shares, New Issues	695,428
Non Cash Compensation Research and Development Expenses			$ 455,809	$ 0	455,809
Common Stock [Member]
Stock Issued During Period, Shares, New Issues				4,929,523
Opus [Member]
Stock Issued During Period, Shares, New Issues			2,000,000
Non Cash Compensation Research and Development Expenses			$ 134,000
National Holdings [Member]
Equity Method Investment, Ownership Percentage						6.70%
Research Development Expenses [Member]
Prepaid research and development			1,719,828		1,719,828
Two Thousand Twelve Issuance [Member]
Legal Expenses Reimbursed To Agent		$ 80,000
Advisory Fees Expenses Private Placement		$ 150,000
Lfb Group [Member]
Other research and development			1,447,000	$ 0
Accounts Payable			$ 56,000		$ 56,000
Private Placement [Member] \| Two Thousand Twelve Issuance [Member]
Agent Cash Commission Percentage On Proceeds From Shares Issuance		10.00%
Series Preferred Stock [Member] \| Two Thousand Eleven Issuance [Member]
Warrant Term			5 years
Agent Warrant Percentage On Issuance Of Shares			10.00%
Agent Non Accountable Expense Percentage On Gross Proceeds From Share Issuance			2.00%

Label	Element	Value
Stock Issued During Period, Value, Restricted Stock Award, Gross	us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross	$ 1,150
Stock Issued During Period Value Of Replacement Restricted Preferred Stock To Employees	tgtx_StockIssuedDuringPeriodValueOfReplacementRestrictedPreferredStockToEmployees	0
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	9,655,816
Common Stock Issued During Period Value In Exchange For License Option	tgtx_CommonStockIssuedDuringPeriodValueInExchangeForLicenseOption	297,000
Stock Issued During Period Value Conversion Of Note Payable To Preferred Stock	tgtx_StockIssuedDuringPeriodValueConversionOfNotePayableToPreferredStock	55,271
Common Stock Issued During Period Value To Founders In Exchange For Seed Capital	tgtx_CommonStockIssuedDuringPeriodValueToFoundersInExchangeForSeedCapital	106,578
Stock Issued During Period, Value, Other	us-gaap_StockIssuedDuringPeriodValueOther	322,964
Non Controlling Interest In Subsidiary [Member]
Net Income (Loss), Including Portion Attributable To Noncontrolling Interest	us-gaap_ProfitLoss	(35,997)
Stock Issued During Period, Value, Other	us-gaap_StockIssuedDuringPeriodValueOther	47,678
Common Stock [Member]
Stock Issued During Period, Value, Restricted Stock Award, Gross	us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross	1,150
Stock Issued During Period Value Of Replacement Restricted Preferred Stock To Employees	tgtx_StockIssuedDuringPeriodValueOfReplacementRestrictedPreferredStockToEmployees	(1,150)
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	$ 4,930
Stock Issued During Period Shares Of Replacement Restricted Preferred Stock To Employees	tgtx_StockIssuedDuringPeriodSharesOfReplacementRestrictedPreferredStockToEmployees	(1,150,000)
Common Stock Issued During Period Value In Exchange For License Option	tgtx_CommonStockIssuedDuringPeriodValueInExchangeForLicenseOption	$ 132
Stock Issued During Period, Shares, Other	us-gaap_StockIssuedDuringPeriodSharesOther	(2,500,124)
Common Stock Issued During Period Value To Founders In Exchange For Seed Capital	tgtx_CommonStockIssuedDuringPeriodValueToFoundersInExchangeForSeedCapital	$ 2,500
Common Stock Issued During Period Shares In Exchange For License Option	tgtx_CommonStockIssuedDuringPeriodSharesInExchangeForLicenseOption	132,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross	us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross	1,150,000
Common Stock Issued During Period Shares To Founders In Exchange For Seed Capital	tgtx_CommonStockIssuedDuringPeriodSharesToFoundersInExchangeForSeedCapital	2,500,000
Stock Issued During Period, Value, Other	us-gaap_StockIssuedDuringPeriodValueOther	$ (2,501)
Preferred Stock [Member]
Stock Issued During Period Value Of Replacement Restricted Preferred Stock To Employees	tgtx_StockIssuedDuringPeriodValueOfReplacementRestrictedPreferredStockToEmployees	$ 129
Stock Issued During Period Shares Conversion Of Note Payable To Preferred Stock	tgtx_StockIssuedDuringPeriodSharesConversionOfNotePayableToPreferredStock	2,763
Stock Issued During Period Shares Of Replacement Restricted Preferred Stock To Employees	tgtx_StockIssuedDuringPeriodSharesOfReplacementRestrictedPreferredStockToEmployees	129,375
Stock Issued During Period, Shares, Other	us-gaap_StockIssuedDuringPeriodSharesOther	281,250
Stock Issued During Period Value Conversion Of Note Payable To Preferred Stock	tgtx_StockIssuedDuringPeriodValueConversionOfNotePayableToPreferredStock	$ 3
Stock Issued During Period, Value, Other	us-gaap_StockIssuedDuringPeriodValueOther	281
Accumulated Deficit During Development Stage [Member]
Net Income (Loss), Including Portion Attributable To Noncontrolling Interest	us-gaap_ProfitLoss	(853,074)
Contingently Issuable Shares [Member]
Stock Issued During Period, Value, Other	us-gaap_StockIssuedDuringPeriodValueOther	6
Additional Paid-In Capital [Member]
Stock Issued During Period Value Of Replacement Restricted Preferred Stock To Employees	tgtx_StockIssuedDuringPeriodValueOfReplacementRestrictedPreferredStockToEmployees	1,021
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	9,650,886
Common Stock Issued During Period Value In Exchange For License Option	tgtx_CommonStockIssuedDuringPeriodValueInExchangeForLicenseOption	296,868
Stock Issued During Period Value Conversion Of Note Payable To Preferred Stock	tgtx_StockIssuedDuringPeriodValueConversionOfNotePayableToPreferredStock	55,268
Common Stock Issued During Period Value To Founders In Exchange For Seed Capital	tgtx_CommonStockIssuedDuringPeriodValueToFoundersInExchangeForSeedCapital	104,078
Stock Issued During Period, Value, Other	us-gaap_StockIssuedDuringPeriodValueOther	277,500
Restricted Preferred Stock [Member]
Adjustments To Additional Paid In Capital, Share-Based Compensation, Restricted Stock Unit Or Restricted Stock Award, Requisite Service Period Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	86,494
Restricted Preferred Stock [Member] \| Additional Paid-In Capital [Member]
Adjustments To Additional Paid In Capital, Share-Based Compensation, Restricted Stock Unit Or Restricted Stock Award, Requisite Service Period Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	$ 86,494